WO2021040502A1 - 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 - Google Patents
이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2021040502A1 WO2021040502A1 PCT/KR2020/011663 KR2020011663W WO2021040502A1 WO 2021040502 A1 WO2021040502 A1 WO 2021040502A1 KR 2020011663 W KR2020011663 W KR 2020011663W WO 2021040502 A1 WO2021040502 A1 WO 2021040502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridin
- dimethyl
- pyrrol
- imidazo
- bromo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 title claims abstract description 17
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 title abstract 3
- 230000000694 effects Effects 0.000 claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 48
- 201000011510 cancer Diseases 0.000 claims abstract description 46
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 29
- 108060006633 protein kinase Proteins 0.000 claims abstract description 29
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 27
- 206010022000 influenza Diseases 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 208
- 125000000217 alkyl group Chemical group 0.000 claims description 94
- 125000001072 heteroaryl group Chemical group 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 71
- 125000001424 substituent group Chemical group 0.000 claims description 47
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 19
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 claims description 15
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 13
- 208000014644 Brain disease Diseases 0.000 claims description 13
- 230000003412 degenerative effect Effects 0.000 claims description 13
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 12
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 12
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 11
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 9
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 101001005609 Homo sapiens Mitogen-activated protein kinase kinase kinase 13 Proteins 0.000 claims description 8
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 claims description 8
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- SPWYNSNVCGOUGP-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CCN(C)C)C SPWYNSNVCGOUGP-NRFANRHFSA-N 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 201000009036 biliary tract cancer Diseases 0.000 claims description 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- RHKNSPGTLFJIRH-QHCPKHFHSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN2CCN(CC2)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN2CCN(CC2)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC RHKNSPGTLFJIRH-QHCPKHFHSA-N 0.000 claims description 4
- QSPOEZGAJAKHGG-UHFFFAOYSA-N CC1=C(C=C(C=C1)C(=O)NCCN(C)C)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br)C Chemical compound CC1=C(C=C(C=C1)C(=O)NCCN(C)C)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br)C QSPOEZGAJAKHGG-UHFFFAOYSA-N 0.000 claims description 4
- JUAIMTVDQSLDLY-UHFFFAOYSA-N CC1=C(C=C(C=C1)NC(=O)CN(C)C)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br)C Chemical compound CC1=C(C=C(C=C1)NC(=O)CN(C)C)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br)C JUAIMTVDQSLDLY-UHFFFAOYSA-N 0.000 claims description 4
- MXMCHRZKCBXDRI-UHFFFAOYSA-N CC1=C(C=C(C=C1)NC(=O)CN2CCN(CC2)C)N3C(=CC(=C3C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br)C Chemical compound CC1=C(C=C(C=C1)NC(=O)CN2CCN(CC2)C)N3C(=CC(=C3C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br)C MXMCHRZKCBXDRI-UHFFFAOYSA-N 0.000 claims description 4
- MZJOGKNMJLVGHV-UHFFFAOYSA-N CC1=C(C=C(C=C1)NC(=O)CN2CCOCC2)N3C(=CC(=C3C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br)C Chemical compound CC1=C(C=C(C=C1)NC(=O)CN2CCOCC2)N3C(=CC(=C3C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br)C MZJOGKNMJLVGHV-UHFFFAOYSA-N 0.000 claims description 4
- GNDYVSXVQXDTFZ-UHFFFAOYSA-N CC1=CC(=C(N1C2=C(C=CC(=C2)Cl)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=C(C=CC(=C2)Cl)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br GNDYVSXVQXDTFZ-UHFFFAOYSA-N 0.000 claims description 4
- WEDVKXNACWSICM-UHFFFAOYSA-N CC1=CC(=C(N1C2=C(C=CC(=C2)S(=O)(=O)N)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=C(C=CC(=C2)S(=O)(=O)N)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br WEDVKXNACWSICM-UHFFFAOYSA-N 0.000 claims description 4
- FVEDUJLDWZUBPI-UHFFFAOYSA-N CC1=CC(=C(N1C2=C(C=CC=C2Cl)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=C(C=CC=C2Cl)Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br FVEDUJLDWZUBPI-UHFFFAOYSA-N 0.000 claims description 4
- ZDROOLJMCNLAKT-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC(=CC=C2)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC(=CC=C2)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br ZDROOLJMCNLAKT-UHFFFAOYSA-N 0.000 claims description 4
- CCNCRQWVZXHLKE-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC(=CC=C2)OCCN3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC(=CC=C2)OCCN3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br CCNCRQWVZXHLKE-UHFFFAOYSA-N 0.000 claims description 4
- XXASCSWPXTUVHB-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC(=CC=C2)S(=O)(=O)N)C)C3=NC4=NC=C(C(=C4N3)NC5=CC=C(C=C5)OCCOC)Br Chemical compound CC1=CC(=C(N1C2=CC(=CC=C2)S(=O)(=O)N)C)C3=NC4=NC=C(C(=C4N3)NC5=CC=C(C=C5)OCCOC)Br XXASCSWPXTUVHB-UHFFFAOYSA-N 0.000 claims description 4
- ZZMRBJZORUNVIK-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC(=CC=C2)S(=O)(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC(=CC=C2)S(=O)(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br ZZMRBJZORUNVIK-UHFFFAOYSA-N 0.000 claims description 4
- HPUUWFFHPBPQFZ-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC3=C(C=C2)OCO3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC3=C(C=C2)OCO3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br HPUUWFFHPBPQFZ-UHFFFAOYSA-N 0.000 claims description 4
- HJIHGTWRSJGVGM-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC3=C(C=C2)OCO3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC=C(C=C6)OCCOC)Br Chemical compound CC1=CC(=C(N1C2=CC3=C(C=C2)OCO3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC=C(C=C6)OCCOC)Br HJIHGTWRSJGVGM-UHFFFAOYSA-N 0.000 claims description 4
- CQYKDYHDMBORSI-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=C(C=C2)C(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=C(C=C2)C(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br CQYKDYHDMBORSI-UHFFFAOYSA-N 0.000 claims description 4
- JPTYXVKYGFFTMF-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=C(C=C2)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=C(C=C2)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br JPTYXVKYGFFTMF-UHFFFAOYSA-N 0.000 claims description 4
- ARPCAUQDUDMNCR-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=C(C=C2)OCCN3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=C(C=C2)OCCN3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br ARPCAUQDUDMNCR-UHFFFAOYSA-N 0.000 claims description 4
- XOVIURLRAAUXDG-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=C(C=C2)S(=O)(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=C(C=C2)S(=O)(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br XOVIURLRAAUXDG-UHFFFAOYSA-N 0.000 claims description 4
- LADDIBHPOZPBQV-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=CC(=C2)C(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=CC(=C2)C(=O)N3CCOCC3)C)C4=NC5=NC=C(C(=C5N4)NC6=CC(=CC=C6)S(=O)(=O)N)Br LADDIBHPOZPBQV-UHFFFAOYSA-N 0.000 claims description 4
- YPZXYQLZUNXUCP-UHFFFAOYSA-N CC1=CC(=C(N1C2=CC=CC=C2Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CC=CC=C2Cl)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br YPZXYQLZUNXUCP-UHFFFAOYSA-N 0.000 claims description 4
- JMTQLRYNSWBBPJ-UHFFFAOYSA-N CC1=CC(=C(N1C2=CN=CC=C2)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1C2=CN=CC=C2)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br JMTQLRYNSWBBPJ-UHFFFAOYSA-N 0.000 claims description 4
- LUKRDCYEMXADMS-UHFFFAOYSA-N CC1=CC(=C(N1CC2=CC=NC=C2)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br Chemical compound CC1=CC(=C(N1CC2=CC=NC=C2)C)C3=NC4=NC=C(C(=C4N3)NC5=CC(=CC=C5)S(=O)(=O)N)Br LUKRDCYEMXADMS-UHFFFAOYSA-N 0.000 claims description 4
- KZUOUOMEBDSEQB-QHCPKHFHSA-N CCN(CC)CCNC(=O)C1=CC(=CC=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C Chemical compound CCN(CC)CCNC(=O)C1=CC(=CC=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C KZUOUOMEBDSEQB-QHCPKHFHSA-N 0.000 claims description 4
- BXFBHQFIHTYCIH-QHCPKHFHSA-N CCN(CC)CCNC(=O)C1=CC=C(C=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C Chemical compound CCN(CC)CCNC(=O)C1=CC=C(C=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C BXFBHQFIHTYCIH-QHCPKHFHSA-N 0.000 claims description 4
- PLGIZJLMXSZNJO-SFHVURJKSA-N CCNS(=O)(=O)C1=CC=CC(=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)N2C(=CC(=C2C)C3=NC4=NC=C(C(=C4N3)N[C@H]5CCN(C5)S(=O)(=O)CC)Br)C PLGIZJLMXSZNJO-SFHVURJKSA-N 0.000 claims description 4
- FRULESDDJURMNJ-FQEVSTJZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C FRULESDDJURMNJ-FQEVSTJZSA-N 0.000 claims description 4
- CLACMJXNGZJBNR-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C CLACMJXNGZJBNR-QHCPKHFHSA-N 0.000 claims description 4
- DEEQCBLBWWDQGB-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)C(=O)N6CCN(CC6)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)C(=O)N6CCN(CC6)C)C)C DEEQCBLBWWDQGB-QHCPKHFHSA-N 0.000 claims description 4
- PGOIAVDZWKUUTN-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)C(=O)N6CCOCC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)C(=O)N6CCOCC6)C)C PGOIAVDZWKUUTN-QFIPXVFZSA-N 0.000 claims description 4
- AWRINZIYPCALKP-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)NC(=O)CN(C)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)NC(=O)CN(C)C)C)C AWRINZIYPCALKP-NRFANRHFSA-N 0.000 claims description 4
- IMHKJJMSYWVINE-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)NC(=O)CN6CCOCC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=C(C=C5)NC(=O)CN6CCOCC6)C)C IMHKJJMSYWVINE-QHCPKHFHSA-N 0.000 claims description 4
- KETOSJPFBNIOCP-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)N6CCN(CC6)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)N6CCN(CC6)C)C)C KETOSJPFBNIOCP-QHCPKHFHSA-N 0.000 claims description 4
- QGTRVDDGBAFPNJ-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)N6CCOCC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)N6CCOCC6)C)C QGTRVDDGBAFPNJ-QFIPXVFZSA-N 0.000 claims description 4
- JFDZJDCCXLJSNK-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)NCCN(C)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)C(=O)NCCN(C)C)C)C JFDZJDCCXLJSNK-QFIPXVFZSA-N 0.000 claims description 4
- VCLOAGHLXNAYNZ-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN(C)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN(C)C)C)C VCLOAGHLXNAYNZ-NRFANRHFSA-N 0.000 claims description 4
- RPQRWSGQGCFXBM-DEOSSOPVSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN6CCN(CC6)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN6CCN(CC6)C)C)C RPQRWSGQGCFXBM-DEOSSOPVSA-N 0.000 claims description 4
- JTJGLNYBQXXBQF-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN6CCOCC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NC(=O)CN6CCOCC6)C)C JTJGLNYBQXXBQF-QHCPKHFHSA-N 0.000 claims description 4
- RJXOAPIKVLVXBR-IBGZPJMESA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C RJXOAPIKVLVXBR-IBGZPJMESA-N 0.000 claims description 4
- ALZDVEUZWKLDPT-HNNXBMFYSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)S(=O)(=O)N)Cl)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)S(=O)(=O)N)Cl)C ALZDVEUZWKLDPT-HNNXBMFYSA-N 0.000 claims description 4
- QCTIXSGOPHWDBE-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)OCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)OCCN6CCOCC6)C QCTIXSGOPHWDBE-QFIPXVFZSA-N 0.000 claims description 4
- SFUYSVJDHUGTRF-IBGZPJMESA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)OCCOC)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)OCCOC)C SFUYSVJDHUGTRF-IBGZPJMESA-N 0.000 claims description 4
- FPFOJAXMYPLIFT-INIZCTEOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)N)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)N)C FPFOJAXMYPLIFT-INIZCTEOSA-N 0.000 claims description 4
- AWHQXQVJQQVHAJ-FQEVSTJZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)N6CCOCC6)C AWHQXQVJQQVHAJ-FQEVSTJZSA-N 0.000 claims description 4
- VTAGDUDUIJKBOY-KRWDZBQOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)NC)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC(=CC=C5)S(=O)(=O)NC)C VTAGDUDUIJKBOY-KRWDZBQOSA-N 0.000 claims description 4
- SFFBFTYNUAZHMK-INIZCTEOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC6=C(C=C5)OCO6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC6=C(C=C5)OCO6)C SFFBFTYNUAZHMK-INIZCTEOSA-N 0.000 claims description 4
- VRAVNWIBZWSUBR-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N(C)CCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N(C)CCN(C)C)C VRAVNWIBZWSUBR-QFIPXVFZSA-N 0.000 claims description 4
- KIUNFEZMVKCPAZ-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N6CCN(CC6)C)C KIUNFEZMVKCPAZ-QFIPXVFZSA-N 0.000 claims description 4
- DEMLPSYWHXUJGZ-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)N6CCOCC6)C DEMLPSYWHXUJGZ-NRFANRHFSA-N 0.000 claims description 4
- TYJDSXORSRPUSN-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN(C)C)C TYJDSXORSRPUSN-NRFANRHFSA-N 0.000 claims description 4
- CRUCCIOYMRZMTB-DEOSSOPVSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN6CCN(CC6)C)C CRUCCIOYMRZMTB-DEOSSOPVSA-N 0.000 claims description 4
- FZIDQNJTWDXISK-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)NCCN6CCOCC6)C FZIDQNJTWDXISK-QHCPKHFHSA-N 0.000 claims description 4
- OVDPPYWTOMBMFG-KRWDZBQOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)O)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)C(=O)O)C OVDPPYWTOMBMFG-KRWDZBQOSA-N 0.000 claims description 4
- FTXWSEWSYRYNNG-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C FTXWSEWSYRYNNG-QFIPXVFZSA-N 0.000 claims description 4
- ONLVFGISTSYZPH-IBGZPJMESA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCOC)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCOC)C ONLVFGISTSYZPH-IBGZPJMESA-N 0.000 claims description 4
- ICJLTSAGNPBPJU-INIZCTEOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)S(=O)(=O)N)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)S(=O)(=O)N)C ICJLTSAGNPBPJU-INIZCTEOSA-N 0.000 claims description 4
- OZIXJVWBQBDYOP-FQEVSTJZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)S(=O)(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)S(=O)(=O)N6CCOCC6)C OZIXJVWBQBDYOP-FQEVSTJZSA-N 0.000 claims description 4
- SMHCXPVBKCHAHT-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N(C)CCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N(C)CCN(C)C)C SMHCXPVBKCHAHT-QFIPXVFZSA-N 0.000 claims description 4
- KNTPPWFJAREMRJ-KRWDZBQOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N)C KNTPPWFJAREMRJ-KRWDZBQOSA-N 0.000 claims description 4
- CCDINAZZDDKPRI-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCN(CC6)C)C CCDINAZZDDKPRI-QFIPXVFZSA-N 0.000 claims description 4
- KRRAGOABOIDARO-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCOCC6)C KRRAGOABOIDARO-NRFANRHFSA-N 0.000 claims description 4
- SGKLHEGIHGNHJH-DEOSSOPVSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCCN6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCCN6CCN(CC6)C)C SGKLHEGIHGNHJH-DEOSSOPVSA-N 0.000 claims description 4
- LLLHADFTAJAISP-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCCN6CCOCC6)C LLLHADFTAJAISP-QHCPKHFHSA-N 0.000 claims description 4
- NRJHZGVYOHNQIP-FQEVSTJZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)NCN(C)C)C NRJHZGVYOHNQIP-FQEVSTJZSA-N 0.000 claims description 4
- XSTPWOGVWQRXQA-KRWDZBQOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)O)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)O)C XSTPWOGVWQRXQA-KRWDZBQOSA-N 0.000 claims description 4
- QKFILIJRYKNWJT-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)N6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)N6CCN(CC6)C)C QKFILIJRYKNWJT-QFIPXVFZSA-N 0.000 claims description 4
- IHBPKPSYCGRFKY-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)N6CCOCC6)C IHBPKPSYCGRFKY-NRFANRHFSA-N 0.000 claims description 4
- OYYJQSDINALFRV-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)NCCN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)C(=O)NCCN(C)C)C OYYJQSDINALFRV-NRFANRHFSA-N 0.000 claims description 4
- XELACDNSJHLMHB-FQEVSTJZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CN(C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CN(C)C)C XELACDNSJHLMHB-FQEVSTJZSA-N 0.000 claims description 4
- IEQOXHFQHHVZPT-QHCPKHFHSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CN6CCN(CC6)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5C)NC(=O)CN6CCN(CC6)C)C IEQOXHFQHHVZPT-QHCPKHFHSA-N 0.000 claims description 4
- RWKDUVXGPYCACK-KRWDZBQOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC=C5)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC=C5)C RWKDUVXGPYCACK-KRWDZBQOSA-N 0.000 claims description 4
- AKKQLXWZBOXHBQ-INIZCTEOSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC=C5Cl)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Br)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC=C5Cl)C AKKQLXWZBOXHBQ-INIZCTEOSA-N 0.000 claims description 4
- LMQAMZBATZYFKH-IBGZPJMESA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=C(C=CC(=C5)NS(=O)(=O)C)C)C LMQAMZBATZYFKH-IBGZPJMESA-N 0.000 claims description 4
- ULXHCKOEIXLUFY-QFIPXVFZSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=CC=C(C=C5)OCCN6CCOCC6)C ULXHCKOEIXLUFY-QFIPXVFZSA-N 0.000 claims description 4
- VKVODUVMGQDQHC-NRFANRHFSA-N CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCOCC6)C Chemical compound CCS(=O)(=O)N1CC[C@@H](C1)NC2=C3C(=NC=C2Cl)N=C(N3)C4=C(N(C(=C4)C)C5=CC=CC(=C5)C(=O)N6CCOCC6)C VKVODUVMGQDQHC-NRFANRHFSA-N 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- MKDKJNKDLSZSLV-DEOSSOPVSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NC(CN2CCN(CC2)C)=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NC(CN2CCN(CC2)C)=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC MKDKJNKDLSZSLV-DEOSSOPVSA-N 0.000 claims description 3
- LGDMURPOHQWWPA-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)C(=O)N2CCOCC2)C)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)C(=O)N2CCOCC2)C)C)NC=2C=C(C=CC2)S(=O)(=O)N LGDMURPOHQWWPA-UHFFFAOYSA-N 0.000 claims description 3
- FGAJJLRRLJGMBW-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=CC(=CC=C2)OCCOC)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=CC(=CC=C2)OCCOC)C)NC=2C=C(C=CC2)S(=O)(=O)N FGAJJLRRLJGMBW-UHFFFAOYSA-N 0.000 claims description 3
- KSTAFUGECYSKAI-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=CC=CC=C2)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=CC=CC=C2)C)NC=2C=C(C=CC2)S(=O)(=O)N KSTAFUGECYSKAI-UHFFFAOYSA-N 0.000 claims description 3
- DGCJRTJNRKOKQT-QFIPXVFZSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C(=C(C=CC2)NC(CN2CCOCC2)=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C(=C(C=CC2)NC(CN2CCOCC2)=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC DGCJRTJNRKOKQT-QFIPXVFZSA-N 0.000 claims description 3
- OYBANAXRUFZOAY-FQEVSTJZSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN(C)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN(C)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC OYBANAXRUFZOAY-FQEVSTJZSA-N 0.000 claims description 3
- OJJWCMYQUPFQHH-QFIPXVFZSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN2CCOCC2)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NC(CN2CCOCC2)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC OJJWCMYQUPFQHH-QFIPXVFZSA-N 0.000 claims description 3
- MUOVPMNIYGMOOH-SFHVURJKSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NS(=O)(=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)NS(=O)(=O)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC MUOVPMNIYGMOOH-SFHVURJKSA-N 0.000 claims description 3
- HXRKEKIQYPAZAI-QFIPXVFZSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2C)NC(CCN(C)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2C)NC(CCN(C)C)=O)C)N[C@@H]2CN(CC2)S(=O)(=O)CC HXRKEKIQYPAZAI-QFIPXVFZSA-N 0.000 claims description 3
- JOTKXEFDFJWXGI-IBGZPJMESA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NS(=O)(=O)C)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NS(=O)(=O)C)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC JOTKXEFDFJWXGI-IBGZPJMESA-N 0.000 claims description 3
- KNQDQBOZKWAHNJ-INIZCTEOSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC KNQDQBOZKWAHNJ-INIZCTEOSA-N 0.000 claims description 3
- HIMSYTBPFAZQPL-HNNXBMFYSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC=C2Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC=C2Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC HIMSYTBPFAZQPL-HNNXBMFYSA-N 0.000 claims description 3
- XFIMGCQQRYZXOA-HNNXBMFYSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC(=C(C=C2)Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC(=C(C=C2)Cl)Cl)C)N[C@@H]2CN(CC2)S(=O)(=O)CC XFIMGCQQRYZXOA-HNNXBMFYSA-N 0.000 claims description 3
- RCHAUQLVXFRUCL-FQEVSTJZSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC(=CC=C2)N2CCOCC2)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC(=CC=C2)N2CCOCC2)C)N[C@@H]2CN(CC2)S(=O)(=O)CC RCHAUQLVXFRUCL-FQEVSTJZSA-N 0.000 claims description 3
- XRYKSZFKGITMMW-FQEVSTJZSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC=C(C=C2)N2CCOCC2)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=CC=C(C=C2)N2CCOCC2)C)N[C@@H]2CN(CC2)S(=O)(=O)CC XRYKSZFKGITMMW-FQEVSTJZSA-N 0.000 claims description 3
- DOOCRVNTHCACMN-SFHVURJKSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C=2C(=C(C=CC2)NS(=O)(=O)C)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C=2C(=C(C=CC2)NS(=O)(=O)C)C)C)N[C@@H]2CN(CC2)S(=O)(=O)CC DOOCRVNTHCACMN-SFHVURJKSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010061825 Duodenal neoplasm Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 101001018157 Homo sapiens Mitogen-activated protein kinase kinase kinase 20 Proteins 0.000 claims description 3
- 101001018149 Homo sapiens Mitogen-activated protein kinase kinase kinase 21 Proteins 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 3
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims description 3
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 claims description 3
- 102100033116 Mitogen-activated protein kinase kinase kinase 20 Human genes 0.000 claims description 3
- 102100033054 Mitogen-activated protein kinase kinase kinase 21 Human genes 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000005890 Neuroma Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 206010054184 Small intestine carcinoma Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 206010044002 Tonsil cancer Diseases 0.000 claims description 3
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 206010009259 cleft lip Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000000312 duodenum cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 208000010749 gastric carcinoma Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000011587 gastric lymphoma Diseases 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010235 heart cancer Diseases 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 208000006359 hepatoblastoma Diseases 0.000 claims description 3
- 208000037797 influenza A Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 201000003175 male breast cancer Diseases 0.000 claims description 3
- 208000010907 male breast carcinoma Diseases 0.000 claims description 3
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 201000000349 mediastinal cancer Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000009612 pediatric lymphoma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 201000003437 pleural cancer Diseases 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 208000020615 rectal carcinoma Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 208000037968 sinus cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 79
- 125000004432 carbon atom Chemical group C* 0.000 description 67
- 230000002401 inhibitory effect Effects 0.000 description 43
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 31
- -1 imidazopyridine derivative compound Chemical class 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 26
- 108091000080 Phosphotransferase Proteins 0.000 description 24
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 24
- 102000020233 phosphotransferase Human genes 0.000 description 24
- 125000002947 alkylene group Chemical group 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 230000000840 anti-viral effect Effects 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 239000013642 negative control Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000001308 synthesis method Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 206010016654 Fibrosis Diseases 0.000 description 12
- 235000021314 Palmitic acid Nutrition 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 9
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000009702 cancer cell proliferation Effects 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 102200092160 rs34637584 Human genes 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229910020008 S(O) Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 230000004611 cancer cell death Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000005880 cancer cell killing Effects 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000004474 heteroalkylene group Chemical group 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229940124786 LRRK2 inhibitor Drugs 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 2
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 2
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000018546 Paxillin Human genes 0.000 description 2
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000005232 imidazopyridines Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OTTXCOAOKOEENK-UHFFFAOYSA-N 2,2-difluoroethenone Chemical group FC(F)=C=O OTTXCOAOKOEENK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ZPPUMAMZIMPJGP-UHFFFAOYSA-N 2-methyl-2-[3-methyl-4-[[4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]pyrazol-1-yl]propanenitrile Chemical compound C1=C(C(F)(F)F)C(NC)=NC(NC=2C(=NN(C=2)C(C)(C)C#N)C)=N1 ZPPUMAMZIMPJGP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- JBGLFWKCDPUPKK-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)C(=O)N2CCN(CC2)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)N=C(N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)C(=O)N2CCN(CC2)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N JBGLFWKCDPUPKK-UHFFFAOYSA-N 0.000 description 1
- JUCWYXUZTSQPRJ-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C(=CC=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C(=CC=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N JUCWYXUZTSQPRJ-UHFFFAOYSA-N 0.000 description 1
- GUOUOKWKXNNUPK-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=C(C=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N GUOUOKWKXNNUPK-UHFFFAOYSA-N 0.000 description 1
- SDKMICWAVBWTFY-UHFFFAOYSA-N BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N Chemical compound BrC=1C(=C2C(=NC1)NC(=N2)C2=C(N(C(=C2)C)C2=C(C=CC(=C2)NS(=O)(=O)C)C)C)NC=2C=C(C=CC2)S(=O)(=O)N SDKMICWAVBWTFY-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MNUONHZJRPCMFI-QFIPXVFZSA-N C(C)S(=O)(=O)N1C[C@H](CC1)NC1=C2C(=NC=C1)NC(=N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)C(=O)N2CCOCC2)C Chemical compound C(C)S(=O)(=O)N1C[C@H](CC1)NC1=C2C(=NC=C1)NC(=N2)C2=C(N(C(=C2)C)C=2C=C(C=CC2)C(=O)N2CCOCC2)C MNUONHZJRPCMFI-QFIPXVFZSA-N 0.000 description 1
- 0 C1=CC=C*1c1ccccc1 Chemical compound C1=CC=C*1c1ccccc1 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- SXLAVENZBAHNKS-UHFFFAOYSA-N CC(C1Nc(cc2)ccc2OCCOC)(C=Nc2c1nc(-c(cc1C)c(C)[n]1-c1cccc(S(N)(=O)=O)c1)[nH]2)Br Chemical compound CC(C1Nc(cc2)ccc2OCCOC)(C=Nc2c1nc(-c(cc1C)c(C)[n]1-c1cccc(S(N)(=O)=O)c1)[nH]2)Br SXLAVENZBAHNKS-UHFFFAOYSA-N 0.000 description 1
- KXEMTKMIEPQGOU-UHFFFAOYSA-N CCS(N(CC1)CC1Nc1c2nc(-c(cc3C)c(C)[n]3-c3cccc(C(NCCN4CCN(C)CC4)=O)c3)[nH]c2ncc1[Br]=C)(=O)=O Chemical compound CCS(N(CC1)CC1Nc1c2nc(-c(cc3C)c(C)[n]3-c3cccc(C(NCCN4CCN(C)CC4)=O)c3)[nH]c2ncc1[Br]=C)(=O)=O KXEMTKMIEPQGOU-UHFFFAOYSA-N 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JSNUSEWFTOQURD-UHFFFAOYSA-N Cc1cc(-c([nH]c2ncc3Br)nc2c3Nc2cc(S(N)(=N)=O)ccc2)c(C)[n]1-c(cc1)ccc1S(N1CCOCC1)(=C)=O Chemical compound Cc1cc(-c([nH]c2ncc3Br)nc2c3Nc2cc(S(N)(=N)=O)ccc2)c(C)[n]1-c(cc1)ccc1S(N1CCOCC1)(=C)=O JSNUSEWFTOQURD-UHFFFAOYSA-N 0.000 description 1
- NAMRIKSAICFKFC-UHFFFAOYSA-N Cc1cc(-c2nc(ncc(Br)c3Nc4cccc(C)c4)c3[nH]2)c(C)[n]1-c1cc(NC(CN2CCN(C)CC2)=O)ccc1C Chemical compound Cc1cc(-c2nc(ncc(Br)c3Nc4cccc(C)c4)c3[nH]2)c(C)[n]1-c1cc(NC(CN2CCN(C)CC2)=O)ccc1C NAMRIKSAICFKFC-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 101710190344 Heat shock factor protein 1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010068305 MAP Kinase Kinase 5 Proteins 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- UJRFHPURILXTNM-UHFFFAOYSA-N O1COC2=C1C=CC(=C2)NC2=C1C(=NC=C2Br)NC(=N1)C1=C(N(C(=C1)C)C=1C=C(C=CC1)S(=O)(=O)N)C Chemical compound O1COC2=C1C=CC(=C2)NC2=C1C(=NC=C2Br)NC(=N1)C1=C(N(C(=C1)C)C=1C=C(C=CC1)S(=O)(=O)N)C UJRFHPURILXTNM-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- CMIBWIAICVBURI-ZETCQYMHSA-N tert-butyl (3s)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](N)C1 CMIBWIAICVBURI-ZETCQYMHSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to an imidazopyridine derivative and a pharmaceutical composition containing the same as an active ingredient, and more particularly, to inhibit the activity of protein kinase to prevent or treat cancer, degenerative brain disease, non-alcoholic fatty liver disease, influenza, etc. It relates to an imidazopyridine derivative that can be used and a pharmaceutical composition containing the same as an active ingredient.
- Kinases mediate reactions that transfer the phosphate groups of high-energy molecules, especially ATP, to the substrate.
- Kinase plays a role in stabilizing the phosphate anhydride bond and increasing the reaction rate by placing the substrate and the phosphate group at a specific position.
- the transition state that appears by interacting with a negatively charged phosphate group is in most cases electrostatically stabilized through a positively charged surrounding amino acid, and some kinases are also coordinated with a phosphate group using a metal cofactor.
- Kinases can be divided into various groups, such as protein kinases, lipid kinases, and carbohydrate kinases, depending on their substrates and properties. Proteins, lipids, or carbohydrates can change their activity, reactivity, and ability to bind to other molecules depending on their phosphorylation state. Kinases have a wide range of effects on intracellular signal transduction and regulate complex biological mechanisms within cells. Some molecules are enhanced or inhibited through phosphorylation, and their ability to interact with other molecules can be modulated. Because many kinases respond to environmental conditions or signals, cells can control molecules within cells depending on the situation through kinases. Therefore, kinases play a very important role in cell growth, differentiation, proliferation, survival, metabolism, signaling, cell transport, secretion, and numerous other cellular response pathways.
- Protein kinase increases or decreases the activity of a protein, can be a marker for stabilization or degradation, can be placed in a specific cell compartment, and can initiate or disrupt interactions with other proteins.
- Protein kinases are known to account for most of the total kinases, and have been an important research subject. Protein kinases, together with phosphatase, play a role in protein and enzyme regulation as well as cell signaling. Cellular proteins are subject to numerous covalent bonds, but because there are not many reversible covalent bonds like phosphorylation, phosphorylation of proteins plays a regulatory function. It can be described as having. Protein kinases often have multiple substrates, and sometimes a specific protein can act as a substrate for more than one kinase.
- protein kinases are named using factors that regulate their activity. For example, a calmodulin dependent protein kinase is regulated by calmodulin. Sometimes kinases are divided into subgroups. For example, type 1 and type 2 cyclic AMP-dependent protein kinases consist of the same enzymatic subunit, but other regulatory subunits are regulated by binding to cyclic AMP.
- Protein kinase is an enzyme that plays an important role in the intracellular signaling process through the phosphorylation reaction of hydroxy groups present in tyrosine, serine, or threonine residues of proteins. , Plays an important role in the transduction of growth factor signals that induce cell growth, differentiation and proliferation (Melnikova, I. et al., Nature Reviews Drug Discovery, 3(2004), 993).
- MAPK mitogen-activated protein kinase
- MAPK mitogen-activated protein kinase
- MAPK is activated by phosphorylation by MAPK kinase (MAP2K or MAPKK) at certain tyrosine and threonine residues
- MAP2K is activated by phosphorylation by MAP2K kinase (MAP3K, MAPKKK) at serine and serine/threonine residues.
- MAP3K group includes several, including A/B/C-Raf, MEKK1/4, ASK1/2, MLK1/2/3, and MEKK2/3, and several, including cytokines, proliferative factors and environmental stress.
- Several mechanisms are involved in the activation of MAP3K following extracellular stimulation.
- LRRK2 leucin-rich repeat kinase-2
- GTP hydrolase guanosine triphosphatase
- serine/threonine kinase activity in one protein.
- the expressed LRRK2 has been observed in various organs and tissues including the brain, and is present in the cytoplasm or the cell membrane and the outer mitochondrial membrane at the cellular level.
- LRRK2 has been reported to be associated with impairment of mild cognitive impairment associated with Alzheimer's disease, L-Dopa induced dyskinesia, and CNS disorders associated with neuronal progenitor differentiation.
- the G2019S mutation of LRRK2 is associated with an increase in the incidence of acute myeloid leukemia (AML) as well as non-skin cancer such as kidney cancer, breast cancer, lung cancer, and prostate cancer.
- AML acute myeloid leukemia
- non-skin cancer such as kidney cancer, breast cancer, lung cancer, and prostate cancer.
- mutant LRRK2 is also associated with amyotrophic lateral sclerosis, rheumatoid arthritis and ankylosing spondylitis.
- Patent Document 1 Korean Patent Application No. 10-2018-0021255
- Patent Document 2 International Publication Patent WO 2011/038572
- One aspect of the present invention is to provide an imidazopyridine derivative compound capable of inhibiting protein kinase activity.
- Another aspect of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, degenerative brain disease, non-alcoholic fatty liver disease, influenza, and the like by inhibiting protein kinase activity by containing an imidazopyridine derivative compound as an active ingredient.
- a compound represented by the following Formula 1 or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof is provided:
- Ar is C 6 -C 20 aryl or 5 to 20 membered heteroaryl
- R 1 to R 4 , l, m and n are the same as defined in Formula 2.
- R 1 to R 4 , m and n are the same as the definition of Formula 2, p is an integer of 0 to 2, R 5 and R 6 are each independently of each other, hydrogen, halogen, hydroxy, cyanide Furnace, nitro, C 1 -C 20 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxyalkyl, C 1 -C 6 aminoalkyl, C 2 -C 20 al Kenyl, C 2 -C 20 alkynyl, C 1 -C 8 alkoxy, C 3 -C 12 cycloalkyl, C 4 -C 12 cycloalkylalkyl, 3 to 12 membered heterocyclyl, 3 to 12 membered heterocyclylalkyl , C 6 -C 20 aryl and 5 to 20 membered heteroaryl, wherein the alkyl, haloalkyl, hydroxyalkyl, al
- R 1 to R 6 , m, n and p are the same as defined in Formula 5.
- the compound represented by Formula 1 may be a compound selected from the group consisting of the following compounds, or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof:
- cancer degenerative brain disease, non-alcoholic fatty liver disease containing the compound represented by Formula 1 or a stereoisomer, solvate, hydrate or pharmaceutically acceptable salt thereof as an active ingredient And it provides a pharmaceutical composition for preventing or treating a disease selected from the group consisting of influenza.
- These compounds can inhibit protein kinase activity.
- the protein kinase may be one or more selected from the group consisting of MLK1, MLK2, MLK3, MLK4, DLK, LZK, ZAK and LRRK2.
- the cancer is pseudomyxoma, intrahepatic biliary tract cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, cleft lip cancer, mycosis fungoides, acute myelogenous leukemia, acute lymphocytic leukemia, basal cell cancer, Ovarian epithelial cancer, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colon cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, diffuse giant B-cell lymphoma, barter bulge Cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, non-sinus cancer, non-small cell lung cancer, non-Hodgkin's lympho
- the degenerative brain disease may be at least one selected from the group consisting of Alzheimer's disease, Down syndrome, Parkinson's disease, Lou Gehrig's disease, dementia, Huntington's disease, multiple sclerosis, proximal lateral sclerosis, stroke, stroke, and mild cognitive impairment.
- the non-alcoholic fatty liver disease may be one or more selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis, cirrhosis, and liver cancer.
- the influenza may be influenza A or influenza B.
- novel imidazopyridine derivative compound and its pharmaceutically acceptable salts according to the present invention have excellent activity against protein kinase
- a pharmaceutical composition containing it as an active ingredient is useful for the prevention or treatment of protein kinase-related diseases. Can be used.
- FIG. 1 is a photograph showing the result of an experiment for inhibiting MLK3 activity of a compound according to an embodiment of the present invention.
- Figure 2 is a graph showing the results of the cancer cell proliferation inhibitory activity test according to the concentration of the compound according to an embodiment of the present invention.
- FIG. 3 is a photograph showing the results of an experiment for inhibiting metastasis of cancer cells of a compound according to an embodiment of the present invention.
- Figure 4 is a graph showing the comparison of the ALT evaluation results for the animal group of the experimental example of the present invention.
- Figure 5 is a graph showing the comparison of the AST evaluation results for the animal group of the experimental example of the present invention.
- Figure 6 is a graph showing the comparison of the evaluation results of the fibrosis area for the animal group of the experimental example of the present invention.
- FIG. 7 is a graph showing LRRK2 phosphorylation inhibition results for examples and comparative compounds of the present invention.
- FIG. 8 is a graph showing a comparison of the neuronal damage protective effects of Examples and Comparative Compounds of the present invention.
- FIG. 9 is a graph showing the comparison of the antiviral effect of the examples of the present invention and the negative control group.
- FIG. 10 is a graph showing the comparison of the antiviral effect of the examples of the present invention and the negative control group.
- 11 is a graph showing the comparison of the antiviral effect of the examples of the present invention and the negative control group.
- 13 is a graph showing the comparison of the antiviral effect of the examples of the present invention and the negative control group.
- 15 is a graph showing the change in weight, which is the result of an antiviral experiment of a compound according to an embodiment of the present invention.
- 16 is a graph showing the survival rate, which is the result of an antiviral experiment of a compound according to an embodiment of the present invention.
- the singular form includes the plural form unless otherwise indicated.
- the substituent includes one or more substituents.
- halo or halogen refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) unless otherwise specified.
- alkyl refers to a saturated monovalent aliphatic hydrocarbon radical, including straight and branched chains having a certain number of carbon atoms.
- the alkyl group is typically 1 to 20 carbon atoms ("C 1 -C 20 alkyl”), preferably 1 to 12 carbon atoms (“C 1 -C 12 alkyl”), more preferably 1 to 8 carbons.
- alkyl group examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, and the like. Includes.
- the alkyl group may be substituted or unsubstituted.
- an alkyl group may be substituted with one or more halogens, up to the total number of hydrogen atoms present on the alkyl moiety.
- C 1 -C 4 alkyl is a halogenated alkyl group, for example a fluorinated alkyl group having 1 to 4 carbon atoms, such as trifluoromethyl (-CF 3 ) or difluoroethyl (-CH 2 CHF 2 ).
- Alkyl groups described herein as being optionally substituted may be substituted with one or more substituents, and substituents are independently selected unless stated otherwise.
- the total number of substituents is equal to the total number of hydrogen atoms on the alkyl moiety to the extent that such substitution satisfies the chemical sense.
- Optionally substituted alkyl groups typically contain 1 to 6 optional substituents, often 1 to 5 optional substituents, preferably 1 to 4 optional substituents, more preferably 1 to 3 optional substituents. .
- An optionally substituted alkyl group may be specifically referred to with reference to a substituent.
- haloalkyl is substituted with one or more halo substituents, typically 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms or 1 or 2
- halo substituents typically 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms or 1 or 2
- a fluorinated alkyl group is typically a fluoroalkyl group substituted with 1, 2 or 3 fluoro atoms, such as a C 1 -C 6 , C 1 -C 4 or C 1 -C 2 fluoroalkyl group specifically May be referred to.
- C 1 -C 4 fluoroalkyl is trifluoromethyl (-CF 3 ), difluoromethyl (-CF 2 H), fluoromethyl (-CFH 2 ), difluoroethyl (-CH 2 CF It includes 2 H) and the like.
- hydroxyalkyl as used herein, unless otherwise specified, is substituted with one or more hydroxy substituents, typically 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, and 1, 2 or It refers to an alkyl group having a certain number of carbon atoms containing 3 hydroxy (ie "C 1 -C 6 hydroxyalkyl").
- C 1 -C 6 hydroxyalkyl includes hydroxymethyl (-CH 2 OH) and 2-hydroxyethyl (-CH 2 CH 2 OH).
- alkoxyalkyl refers to an alkyl group having a certain number of carbon atoms substituted with one or more alkoxy substituents.
- Alkoxyalkyl groups typically contain 1 to 6 carbon atoms in the alkyl moiety and are substituted with 1, 2 or 3 C 1 -C 4 alkyloxy substituents. Such groups are often described herein as C 1 -C 4 alkyloxy-C 1 -C 6 alkyl.
- aminoalkyl refers to an alkyl group having a specific number of carbon atoms substituted with one or more substituted or unsubstituted amino groups, such groups being further defined herein. Aminoalkyl groups typically contain 1 to 6 carbon atoms in the alkyl moiety and are substituted with 1, 2 or 3 amino substituents.
- C 1 -C 6 aminoalkyl is, for example, aminomethyl (-CH 2 NH 2 ), N,N-dimethylaminoethyl (-CH 2 CH 2 N(CH 3 ) 2 ), 3-( N-cyclopropylamino)propyl (-CH 2 CH 2 CH 2 NH-cPr) and N-pyrrolidinylethyl (-CH 2 CH 2 -N-pyrrolidinyl).
- alkenyl refers to an alkyl group, as defined herein, consisting of two or more carbon atoms and one or more carbon-carbon double bonds.
- the alkenyl group is 2 to 20 carbon atoms ("C 2 -C 20 alkenyl"), preferably 2 to 12 carbon atoms ("C 2 -C 12 alkenyl”), more preferably 2 To 8 carbon atoms (“C 2 -C 8 alkenyl”), or 2 to 6 carbon atoms (“C 2 -C 6 alkenyl”), or 2 to 4 carbon atoms ("C 2 -C 4 Alkenyl”).
- alkenyl includes, for example, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, and the like.
- Alkenyl groups are substituted or unsubstituted by the same groups as described herein as suitable for alkyl.
- alkynyl refers to an alkyl group as defined herein consisting of two or more carbon atoms and one or more carbon-carbon triple bonds.
- the alkynyl group is 2 to 20 carbon atoms ("C 2 -C 20 alkynyl”), preferably 2 to 12 carbon atoms ("C 2 -C 12 alkynyl”), more preferably 2 to 8 A carbon atom (“C 2 -C 8 alkynyl”), or 2 to 6 carbon atoms (“C 2 -C 6 alkynyl”), or 2 to 4 carbon atoms (“C 2 -C 4 alkynyl”) ).
- Alkynyl groups are substituted or unsubstituted by the same groups as described herein as suitable for alkyl.
- alkylene refers to a divalent hydrocarbyl group having a certain number of carbon atoms, which can link two different groups together. Often alkylene refers to the group -(CH 2 ) n- (where n is 1 to 8, preferably n is 1 to 4). Where specified, alkylenes may also be substituted with other groups and may contain at least one degree of substitution (ie, alkenylene or alkynylene moiety) or rings. The open valency of the alkylene need not be at the opposite end of the chain.
- alkylene groups such as -CH(Me)-, -CH 2 CH(Me)- and -C(Me) 2 -are also included in the scope of the term "alkylene", and cyclic groups such as cyclopropane
- alkylene groups are substituted or unsubstituted by the same groups as described herein as suitable for alkyl.
- heteroalkylene refers to the foregoing, unless otherwise specified, in which one or more non-contiguous carbon atoms of the alkylene chain have been replaced by -N(R)-, -O-, or -S(O) x -.
- An alkylene group wherein R is hydrogen (H) or a suitable substituent, and x is 0 to 2.
- R is hydrogen (H) or a suitable substituent
- x is 0 to 2.
- the group -O-(CH 2 ) 1-4 - is a "C 2 -C 5 "-heteroalkylene group in which one of the carbon atoms of the corresponding alkylene has been replaced by O.
- Heteroalkylene groups are substituted or unsubstituted by the same groups as described herein as suitable for alkyl.
- alkoxy refers to a monovalent —O-alkyl group in which the alkyl moiety has a certain number of carbon atoms.
- Alkoxy groups are typically 1 to 8 carbon atoms (“C 1 -C 8 alkoxy”), or 1 to 6 carbon atoms (“C 1 -C 6 alkoxy”), or 1 to 4 carbon atoms (“C 1 -C 4 alkoxy”).
- C 1 -C 4 alkoxy is methoxy (-OCH 3 ), ethoxy (-OCH 2 CH 3 ), isopropoxy (-OCH (CH 3 ) 2 ), tert-butyloxy (-OC( CH 3 ) 3 ) and the like.
- Alkoxy groups are unsubstituted or substituted on the alkyl moiety by the same groups as described herein as suitable for alkyl.
- the alkoxy group may be optionally substituted with one or more halo atoms, in particular one or more fluoro atoms, up to the total number of hydrogen atoms present on the alkyl moiety.
- haloalkoxy groups having a certain number of carbon atoms and substituted with one or more halo substituents, eg, when fluorinated, more specifically “fluoroalkoxy” groups, typically such groups having 1 to 6 carbon atoms , Preferably 1 to 4 carbon atoms, often 1 or 2 carbon atoms, and 1, 2 or 3 halo atoms (ie "C 1 -C 6 haloalkoxy", “C 1 -C 4 Haloalkoxy" or "C 1 -C 2 haloalkoxy”).
- the fluorinated alkyl group is typically a fluoroalkoxy group substituted with 1, 2 or 3 fluoro atoms, such as a C 1 -C 6 , C 1 -C 4 or C 1 -C 2 fluoroalkoxy group. May be referred to as.
- C 1 -C 4 fluoroalkoxy is trifluoromethyloxy (-OCF 3 ), difluoromethyloxy (-OCF 2 H), fluoromethyloxy (-OCFH 2 ), difluoroethyloxy ( -OCH 2 CF 2 H) and the like.
- thioalkoxy as used herein, unless otherwise stated, is a monovalent -S wherein the alkyl moiety has a certain number of carbon atoms and is optionally substituted on the alkyl moiety by the same groups as described herein as suitable for alkyl. -Refers to an alkyl group.
- cycloalkyl refers to a non-aromatic, saturated or partially unsaturated carbocyclic ring system containing a certain number of carbon atoms, and through the carbon atoms of the cycloalkyl ring, the base molecule It may be a monocyclic, spirocyclic, bridged or fused bicyclic or polycyclic ring system linked to.
- the cycloalkyl groups of the invention contain 3 to 12 carbon atoms (“C 3 -C 12 cycloalkyl”), preferably 3 to 8 carbon atoms (“C 3 -C 8 cycloalkyl”).
- Representative examples include, for example, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, adamantane, and the like.
- Cycloalkyl groups are substituted or unsubstituted by the same groups as described herein as suitable for alkyl.
- cycloalkylalkyl is used to describe a cycloalkyl ring, typically a C 3 -C 8 cycloalkyl, unless otherwise stated, and refers to an alkylene linking group, typically a C 1 -C 4 alkylene. It is connected to the underlying molecule through. Cycloalkylalkyl groups are often described by the total number of carbon atoms and linking groups in the carbocyclic ring, and typically have 4 to 12 carbon atoms (“C 4 -C 12 cycloalkylalkyl”).
- the cyclopropylmethyl group is a C 4 -cycloalkylalkyl group
- cyclohexylethyl is a C 8 -cycloalkylalkyl
- Cycloalkylalkyl groups are unsubstituted or substituted on the cycloalkyl and/or alkylene moieties by the same groups as described herein as suitable for alkyl.
- a cycloalkylalkyl group is described herein as -LC 3 -C 8 -cycloalkyl, wherein the cycloalkyl group has the indicated number of carbon atoms and -L- refers to an alkylene linking group.
- -L- is a bond, it will be understood that the group is cycloalkyl.
- heterocyclyl refers to a specific number of ring atoms, including one or more heteroatoms selected from N, O and S as ring members.
- heterocyclic refers to a specific number of ring atoms, including one or more heteroatoms selected from N, O and S as ring members.
- the heterocyclic ring is linked to the base molecule through a ring atom, which may be C or N.
- the heterocyclic ring includes a spirocyclic, bridged or fused ring with respect to one or more other heterocyclic or carbocyclic rings, and the spirocyclic, bridged or fused ring itself is unsaturated or aromatic to a degree that satisfies the chemical sense. It may be saturated, partially unsaturated or aromatic, but the point of attachment to the base molecule is the atom of the heterocyclic portion of the ring system.
- the heterocyclic ring contains 1 to 4 heteroatoms, more preferably 1 or 2 ring heteroatoms independent from N, O, and S(O) q as ring members, such heterocyclic ring It does not contain two adjacent oxygen atoms.
- Heterocyclyl groups are unsubstituted or substituted by suitable substituents, for example the same groups as described herein as suitable for alkyl, aryl or heteroaryl. Such substituents may be present on a heterocyclic ring attached to the base molecule, or a spirocyclic, bridged, or fused ring attached thereto.
- the ring N atom may be optionally substituted with a group suitable for an amine such as an alkyl, acyl, carbamoyl, sulfonyl substituent or the like.
- the heterocycle typically comprises a 3 to 12 membered heterocyclyl group, preferably a 3 to 10 membered heterocyclyl group, more preferably a 5 or 6 membered heterocyclyl group according to the definition herein.
- the heterocyclic group contains 3 to 12 ring members (including both carbon and non-carbon heteroatoms), preferably 4 to 7 ring members.
- the substituent comprising a 3-12 membered heterocycle is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, diaazepanyl, tetrahydrofuranyl, tetrahydropyranyl, Selected from tetrahydrothiophenyl, tetrahydrothiopyranyl, morpholinyl or thiomorpholinyl rings, each of which may be optionally substituted as described for a particular substituent to the extent that such substitution is satisfactory to the chemical sense. have.
- N or S When an oxo group is attached to N or S to form a nitro or sulfonyl group, or a specific heteroaromatic ring such as triazine, triazole, tetrazole, oxadiazole, thiadiazole, etc., two It is understood that the following N, O or S atoms are usually connected continuously.
- heterocyclylalkyl may be used to describe a heterocyclic group of a specific size that is linked to the base molecule through an alkylene linking group of a specific length, unless otherwise stated.
- such groups have an optionally substituted 3-12 membered heterocycle attached to the base molecule through a C 1 -C 4 alkylene linking group.
- such groups may be optionally substituted on the alkylene moiety by the same groups as described herein as suitable for an alkyl group and on the heterocyclic moiety by groups described as suitable for a heterocyclic ring.
- heterocyclylalkyl group is described herein as -L-heterocyclylalkyl, wherein the heterocyclylalkyl group has the indicated number of ring atoms and -L- refers to an alkylene linking group.
- -L- is a bond, it will be understood that the group is heterocyclyl.
- aryl refers to an optionally substituted monocyclic or fused bicyclic or polycyclic ring system having the well-known characteristics of aromaticity, unless otherwise stated, wherein one or more rings Contains a fully conjugated pi-electron system.
- the aryl group is a ring member from 6 to 20 carbon atoms ("C 6 -C 20 aryl”), preferably 6 to 14 carbon atoms ("C 6 -C 14 aryl”), more preferably 6 To 12 carbon atoms (“C 6 -C 12 aryl”).
- Fused aryl groups may include aryl rings (e.g., phenyl rings) fused to other aryl or heteroaryl rings, or fused to saturated or partially unsaturated carbocyclic or heterocyclic rings, but to the base molecule on such a fused ring system.
- the point of attachment to is an atom of the aromatic portion of the ring system.
- the aryl group includes phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, or tetrahydronaphthyl.
- Aryl groups are substituted or unsubstituted as further described herein.
- heteroaryl or “heteroaromatic” as used herein, unless otherwise specified, contains a certain number of ring atoms as ring members in an aromatic ring and includes one or more heteroatoms selected from N, O and S. , Refers to a monocyclic or fused bicyclic or polycyclic ring system with the well-known characteristics of aromaticity. The inclusion of heteroatoms allows for aromaticity in the 5-membered and 6-membered rings.
- a heteroaryl group has 5 to 20 ring atoms ("5 to 20 membered heteroaryl”), preferably 5 to 14 ring atoms ("5 to 14 membered heteroaryl”), more preferably 5 to 12 It has a membered ring atom ("5-12 membered heteroaryl”).
- the heteroaryl ring is attached to the base molecule through the ring atom of the heteroaromatic ring to maintain its aromaticity.
- a 6 membered heteroaryl ring may be attached to the base molecule through a ring C atom
- a 5 membered heteroaryl ring may be attached to the base molecule through a ring C or N atom.
- Heteroaryl groups may also be fused to other aryl or heteroaryl rings, or to saturated or partially unsaturated carbocyclic or heterocyclic rings, wherein the point of attachment to the base molecule on such a fused ring system is that of the heteroaromatic portion of the ring system. It is an atom.
- the 5 or 6 membered heteroaryl group is pyrroleyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, pyridinyl and pyri. It is selected from the group consisting of midinyl, pyrazinyl or pyridazinyl rings. Heteroaryl groups are substituted or unsubstituted as further described herein.
- Aryl, heteroaryl and heterocyclyl moieties described herein as optionally substituted may be substituted with one or more substituents independently selected unless otherwise indicated.
- the total number of substituents may be equal to the total number of hydrogen atoms on the aryl, heteroaryl or heterocyclyl moiety, to the extent that such substitution satisfies the chemical sense and maintains aromaticity in the case of aryl and heteroaryl rings.
- Optionally substituted aryl, heteroaryl or heterocyclyl groups are typically 1 to 5 optional substituents, often 1 to 4 optional substituents, preferably 1 to 3 optional substituents, more preferably 1 or 2 Contains four optional substituents.
- arylalkyl refers to an aryl group described herein linked to the base molecule through an alkylene or similar linking group.
- Arylalkyl groups are described by the total number of carbon atoms in the ring and linking group.
- the benzyl group is a C 7 -arylalkyl group
- phenylethyl is a C 8 -arylalkyl.
- the arylalkyl group contains 7 to 16 carbon atoms (“C 7 -C 16 arylalkyl”)
- the aryl moiety contains 6 to 12 carbon atoms
- the alkylene moiety contains 1 to 4 carbon atoms. Contains.
- Such groups may also be represented by -C 1 -C 4 alkylene-C 6 -C 12 aryl.
- heteroarylalkyl is attached to the base molecule through an alkylene linking group, and is different from “arylalkyl” in that at least one ring atom of the aromatic moiety is a heteroatom selected from N, O and S refers to a heteroaryl group.
- Heteroarylalkyl groups are often described herein according to the total number of non-hydrogen atoms (ie, C, N, S and O atoms) of the combined ring and linking group excluding substituents.
- pyridinylmethyl may be referred to as C 7 -heteroarylalkyl.
- unsubstituted heteroarylalkyl groups contain 6 to 20 non-hydrogen atoms (including C, N, S and O atoms), wherein the heteroaryl moiety typically contains 5 to 12 atoms and , The alkylene moiety typically contains 1 to 4 carbon atoms. Such groups may also be represented by -C 1 -C 4 alkylene-5 to 12 membered heteroaryl.
- a heteroarylalkyl group is described herein as -L-heteroarylalkyl, wherein the heteroarylalkyl group has the indicated number of ring atoms and -L- refers to an alkylene linking group. When -L- is a bond, it will be understood that the group is heteroaryl.
- arylalkoxy and “heteroarylalkoxy” refer to an aryl group and a heteroaryl group attached to the base molecule through a heteroalkylene linking group (ie, -O-alkylene-) unless otherwise specified.
- the group is described according to the total number of non-hydrogen atoms (ie, C, N, S and O atoms) in the combined ring and linking group.
- -O-CH 2 - phenyl, -O-CH 2 - pyridin days each C 8 - will be referred to as heteroaryl, alkoxy-alkoxy and C 8 aryl.
- the substituent may be present on the divalent linking group portion or the aryl or heteroaryl portion of the group.
- the substituent optionally present on the alkylene or heteroalkylene moiety is generally the same as described above for the alkyl group or alkoxy group, whereas the substituent optionally present on the aryl or heteroaryl moiety is generally the same as for the aryl group or heteroaryl group. Same as above.
- hydroxy refers to the group -OH unless otherwise stated.
- acyloxy refers to the monovalent group -OC(O)alkyl, unless otherwise specified, wherein the alkyl moiety is a specific number of carbon atoms (typically C 1 -C 8 , preferably C 1 -C 6 or C 1 -C 4 ).
- C 1 -C 4 acyloxy includes -OC(O)C 1 -C 4 alkyl substituents, such as -OC(O)CH 3 .
- acyl refers to a monovalent group -C(O)alkyl, unless otherwise stated, wherein the alkyl moiety is a certain number of carbon atoms (typically C 1 -C 8 , preferably C 1 -C 6 or C 1 -C 4 ) and may be optionally substituted with groups suitable for alkyl, such as -F, -OH or alkoxy.
- optionally substituted -C(O)C 1 -C 4 alkyl is an unsubstituted acyl group such as -C(O)CH 3 (i.e. acetyl) and -C(O)CH 2 CH 3 (i.e.
- acyl groups such as -C(O)CF 3 (trifluoroacetyl), -C(O)CH 2 OH(hydroxyacetyl), -C(O)CH 2 OCH 3 (me Oxyacetyl), -C(O)CF 2 H (difluoroacetyl), and the like.
- acylamino refers to a monovalent group, -NHC(O)alkyl or -NRC(O)alkyl, wherein the alkyl moiety refers to a certain number of carbon atoms (typically C 1 -C 8 , preferably C 1 -C 6 or C 1 -C 4 ), optionally substituted with groups suitable for alkyl.
- C 1 -C 4 acylamino includes -NHC(O)C 1 -C 4 alkyl substituents, such as -NHC(O)CH 3 .
- aryloxy or “heteroaryloxy” as used herein, unless otherwise specified, refer to an optionally substituted -O-aryl or -O-heteroaryl, in each case aryl and heteroaryl are herein As defined in addition to.
- arylamino or “heteroarylamino” refers to an optionally substituted -NH-aryl, -NR-aryl, -NH-heteroaryl or -NR-heteroaryl, unless otherwise specified, and , In each case aryl and heteroaryl are as further defined herein, and R represents a suitable substituent for the amine, such as an alkyl, acyl, carbamoyl or sulfonyl group, and the like.
- cyano refers to the group -C ⁇ N, unless otherwise specified.
- the term “unsubstituted amino” refers to the group -NH 2 unless stated otherwise.
- this term includes a group of the form -NR x R y , wherein each R x and R y is independently hydrogen (H), alkyl, alkenyl, alkynyl, Cycloalkyl, heterocyclyl, acyl, thioacyl, aryl, heteroaryl, cycloalkylalkyl, arylalkyl or heteroarylalkyl, in each case having a certain number of atoms and optionally substituted as described herein.
- alkylamino refers to the group -NR x R y (wherein one of R x and R y is an alkyl moiety and the other is H), and "dialkylamino” refers to -NR x R y (Wherein both R x and R y are alkyl moieties), wherein the alkyl moiety is a specific number of carbon atoms (e.g. -NH-C 1 -C 4 alkyl or -N(C 1 -C 4 alkyl) 2 ).
- the alkyl substituent on the amine contains 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms.
- R x and R y together with the N atom to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each of which is a heterocyclyl or heteroaryl ring Is optionally substituted as described herein for N, O and S(O) x (wherein x is 0 to 2) and may contain 1 to 3 additional heteroatoms as ring members, , These rings do not contain two adjacent oxygen atoms.
- the terms “arbitrary” or “optionally” mean that the event or situation subsequently described need not occur, but the description may include instances where the event or situation occurs and when it does not.
- the present invention provides a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
- Ar is C 6 -C 20 aryl or 5 to 20 membered heteroaryl
- R a , R b and R c are each independently of each other, hydrogen, halogen, hydroxy, cyano, nitro, C 1 -C 20 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl , C 1 -C 6 alkoxyalkyl, C 1 -C 6 aminoalkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 1 -C 8 alkoxy, C 3 -C 12 cycloalkyl, C 4 -C 12 cycloalkylalkyl, 3 to 12 membered heterocyclyl, 3 to 12 membered heterocyclylalkyl, C 6 -C 20 aryl and 5 to 20 membered heteroaryl selected from the group consisting of,
- L is an integer of 0 to 3
- m is an integer of 0 to 3
- the compound represented by Formula 1 may be represented by the following Formula 2.
- R 1 to R 3 , l and m are the same as the definition of Formula 1,
- n is an integer from 0 to 5
- the compound represented by Formula 2 may be represented by the following Formula 3 or Formula 4.
- R 1 to R 4 , l, m and n are the same as defined in Formula 2.
- the compound represented by Formula 2 may be represented by the following Formula 5.
- R 1 to R 4 , m and n are the same as the definition of Formula 2,
- p is an integer from 0 to 2
- R 5 and R 6 are each independently of each other hydrogen, halogen, hydroxy, cyano, nitro, C 1 -C 20 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1- C 6 alkoxyalkyl, C 1 -C 6 aminoalkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 1 -C 8 alkoxy, C 3 -C 12 cycloalkyl, C 4 -C 12 cyclo It is selected from the group consisting of alkylalkyl, 3-12 membered heterocyclyl, 3-12 membered heterocyclylalkyl, C 6 -C 20 aryl and 5-20 membered heteroaryl,
- the compound represented by Formula 5 may be represented by the following Formula 6 or Formula 7.
- R 1 to R 6 , m, n and p are the same as defined in Formula 5.
- the compound represented by Formula 1 may be a compound selected from the group consisting of the following compounds, but is not limited thereto.
- the compound represented by Chemical Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful.
- Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid, etc., aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes.
- Non-toxic organic acids such as dioates, aromatic acids, aliphatic and aromatic sulfonic acids, etc., acetic acid substituted or unsubstituted with one or more halogens selected from the group consisting of F, Cl, Br and I, benzoic acid, citric acid, lactic acid, maleic acid, glucose It is obtained from organic acids such as conic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid and fumaric acid.
- Such pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, i.
- the acid addition salt according to the present invention can be prepared by a conventional method, for example, a precipitate formed by dissolving the derivative of Formula 1 in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc. and adding an organic or inorganic acid May be prepared by filtration and drying, or may be prepared by distilling a solvent and an excess of acid under reduced pressure and then drying to crystallize under an organic solvent.
- an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc.
- a pharmaceutically acceptable metal salt can be made using a base.
- the alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt.
- the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable negative salt (eg, silver nitrate).
- the present invention includes not only the compound represented by Formula 1 and its pharmaceutically acceptable salts, but also solvates, stereoisomers, hydrates, etc. that may be prepared therefrom.
- the solvate may comprise a molecular complex comprising a compound of the present invention and one or more pharmaceutically acceptable solvent molecules, such as ethanol or water.
- the complex in which the solvent molecule is water is also referred to as a hydrate.
- the compounds of the present invention may exist as stereoisomers, such as racemates, enantiomers, or diastereomers.
- Stereoisomers of the compounds of the formulas of the present invention include cis and trans isomers, optical isomers, such as (R) and (S) enantiomers, diastereomers, geometric isomers, rotational isomers, atropisomers, conformational isomers, and of the present invention. Tautomers of the compounds (including compounds exhibiting more than one type of isomerism) and mixtures thereof (eg, racemate and diastereomeric pairs).
- the first type is the aforementioned racemic compound (true racemate) in which one homogeneous form of crystals is produced containing both enantiomers in equimolar amounts.
- the second type is a racemic mixture or aggregate in which two types of crystals each comprising a single enantiomer are produced in equimolar amounts.
- the compounds of the present invention may exhibit tautomeric isomerism and structural isomerism.
- compounds can exist in several tautomeric forms, including enol and imine forms, and keto and enamine forms and geometric isomers and mixtures thereof. All of these tautomeric forms are included within the scope of the compounds of the present invention.
- Tautomers exist as a mixture of a set of tautomers in solution. In solid form, usually one tautomer predominates. While one tautomer may be described, the present invention includes all tautomers of the compounds of the formulas provided.
- some of the compounds of the present invention are capable of forming atropisomers (eg, substituted biaryls).
- Atropisomers are conformational stereoisomers that occur when rotation around a single bond in a molecule is hindered or significantly slowed down because the steric interaction with other parts of the molecule and the substituents at both ends of the single bond is asymmetric.
- the interconversion of atropisomers is slow enough to allow separation and isolation under certain conditions.
- the energy barrier of thermal racemization can be determined by steric hindrance to the free rotation of one or more bonds forming a chiral axis.
- Cis/trans isomers can be separated by conventional techniques well known to those skilled in the art, such as chromatography and fractional crystallization.
- racemate (or racemic precursor) is reacted with a suitable optically active compound, such as an alcohol, or an acid or base such as tartaric acid or 1-phenylethylamine, if the compound contains an acidic or basic moiety. can do.
- a suitable optically active compound such as an alcohol, or an acid or base such as tartaric acid or 1-phenylethylamine, if the compound contains an acidic or basic moiety. can do.
- a suitable optically active compound such as an alcohol, or an acid or base such as tartaric acid or 1-phenylethylamine, if the compound contains an acidic or basic moiety. can do.
- the resulting diastereomeric mixture can be separated by chromatography and/or fractional crystallization, and one or both of the diastereomers can be converted to the corresponding pure enantiomers by means well known to those skilled in the art.
- the present invention also includes isotopically-labeled compounds (the same as recited in one of the formulas provided, but one or more atoms are replaced by an atom having an atomic weight or mass number different from the atomic weight or mass number commonly found in nature).
- Isotopically-labeled compounds of the present invention are generally prepared by conventional techniques known to those of skill in the art or by processes similar to those described herein, using appropriate isotopically-labeled reagents in place of otherwise used non-labeled reagents. Can be.
- the present invention provides a pharmaceutical composition containing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the pharmaceutical composition may be used for preventing and treating a disease selected from the group consisting of cancer, degenerative brain disease, non-alcoholic fatty liver disease, and influenza.
- the compound represented by Formula 1 may inhibit protein kinase activity.
- the MAPK pathway includes the ERK1/2 module, the JNK/p38 module, and the ERK5 module.
- the MAPK 1/2 signaling cascade is activated by ligand binding to receptor tyrosine kinase (RTK), and the activated receptor recruits and phosphorylates the adapter proteins Grb2 and SOS, which in turn is membrane-bound GTPase. Interacts with Ras and causes its activation. In its activated GTP-binding form, Ras recruits and activates Raf kinases (A-Rf, B-Raf, and C-Raf/Raf-1).
- RTK receptor tyrosine kinase
- Raf kinase activates MAPK 1/2 (MKK1/2), which in turn catalyzes the phosphorylation of threonine and tyrosine residues in the activation sequence Thr-Glu-Tyr of ERK1/2.
- the upstream kinase MAP3K
- MAP3K e.g., MEKK1/4, ASK1/2, and MLK1/2/3
- MAP2K3/6 MKK3/6
- MAP2K4 MKK4
- MKK7 MAP2K7
- JNK1 JNK2K2K2K2K2K2K2K3/6
- JNK2K4 JNK2K4
- MKK7 MAP2K7
- JNKs activate several transcription factors including c-Jun, ATF-2, NF-ATc1, HSF-1 and STAT1.
- the kinases upstream of MAP2K5 are MEKK2 and MEKK3.
- LRRK2 or LRRK2 mutations have been found in the majority of patients with degenerative brain diseases. Mutations present in the LRRK2 kinase domain result in enhancement of LRRK2 kinase activity.
- LRRK2 expression is highest in the same area of the brain affected by Parkinson's disease, and LRRK2 is found in the Lewy body, a characteristic of Parkinson's disease.
- LRRK2 mutations are associated with Alzheimer's disease-like pathology, which may partially overlap between neurodegenerative pathways in both Alzheimer's disease and Parkinson's disease.
- degenerative brain diseases such as Parkinson's disease and Alzheimer's disease can be prevented or treated.
- the protein kinase may be MLK family (Mixed lineage kinase family) or LRRK2, and the MLK family may consist of MLK1, MLK2, MLK3, MLK4, DLK, LZK or ZAK.
- the cancer is pseudomyxoma, intrahepatic biliary tract cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, cleft lip cancer, mycosis fungoides, acute myelogenous leukemia, acute lymphocytic leukemia, basal cell cancer, Ovarian epithelial cancer, ovarian germ cell carcinoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colon cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, diffuse giant B-cell lymphoma, barter bulge Cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, non-sinus cancer, non-small cell lung cancer, non-Hodgkin's lympho
- the degenerative brain disease may be at least one selected from the group consisting of Alzheimer's disease, Down syndrome, Parkinson's disease, Lou Gehrig's disease, dementia, Huntington's disease, multiple sclerosis, proximal lateral sclerosis, stroke, stroke, and mild cognitive impairment.
- the non-alcoholic fatty liver disease may be one or more selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis, cirrhosis, and liver cancer.
- the influenza may be influenza A or influenza B.
- the compound represented by Formula 1 according to the present invention can be administered in various oral and parenteral formulations at the time of clinical administration, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. It is prepared using diluents or excipients.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, and water, in one or more compounds of the present invention. It is prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid formulations for oral administration include suspensions, liquid formulations, emulsions or syrups, and include various excipients, such as humectants, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents. I can.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- injectable ester such as ethyl oleate
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, and the like may be used.
- the present invention provides a method for treating cancer comprising administering the compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a subject.
- the therapeutically effective amount refers to an amount capable of improving a symptom or condition of a subject when administered into the body according to an administration method.
- the amount may vary according to the weight, age, sex, state, and family history of the subject to be administered, and the treatment method in the present invention may determine a different amount of dosage according to different conditions for each subject.
- an “effective amount” is an amount useful to treat a proliferative, inflammatory, infectious, neurological or cardiovascular disorder, or an amount effective to treat the disease.
- an “effective amount” of a compound refers to at least a minimum amount capable of inhibiting the proliferation of the disease.
- the compounds and compositions according to the methods of the present invention can be administered using any amount and any route of administration effective to treat a disease.
- the exact amount required will vary from subject to subject depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
- the compounds of the present invention are frequently formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form means a physically separate unit of an agent suitable for the subject to be treated.
- the specific effective dosage level for any particular subject or organism will depend on a variety of factors including the following.
- subject refers to an animal, such as a mammal, such as a human.
- composition of the present invention can be systemically or topically administered to humans and other animals according to the severity of the infection to be treated, orally or parenterally (nasal, transpulmonary, intravenous, rectal, subcutaneous, intramuscular, transdermal, etc.). , Can be administered.
- the dosage of the compound represented by the formula (1) of the present invention, or a pharmaceutically acceptable salt thereof, which is the active ingredient is the age and sex of the patient.
- Weight, disease and degree of treatment are appropriately determined.
- an adult weight 60 kg
- an adult may be appropriately administered in the range of 0.001 to 3,000 mg/Kg per day, divided once or several times, and administered every two days, a week or a month. It can be administered once or multiple times orally or parenterally.
- the dose to be administered to a specific individual or patient should be determined in the light of various related factors such as the patient's weight, age, sex, health status, diet, administration time, administration method, and disease severity, and can be appropriately adjusted or decreased by an expert. It should be understood that the dosage is not intended to limit the scope of the present invention in any way.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage form may contain the following examples of inert diluents commonly used in the art: water or other solvents, solubilizers, and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate. , Benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (e.g.
- oral compositions may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Injectable preparations for example sterile injectable aqueous or lipid-producing suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable diluent or solvent, for example a solution in 1,3-butanediol.
- a non-toxic parenterally acceptable diluent or solvent for example a solution in 1,3-butanediol.
- acceptable vehicles and solvents water, Ringer's solution, U.S.P. And isotonic sodium chloride solution.
- sterilized, fixed oil is conventionally used as a solvent or dispersion medium.
- any blended oil can be used, including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the manufacture of injections.
- Injectable formulations can be sterilized, for example, by filtration through a bacteria-fixing filter, or by incorporating a sterilizing agent in the form of a sterilized solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. have.
- the absorption rate of a compound can depend on its dissolution rate, which can depend on the crystal size and crystal form.
- delayed absorption of a parenterally administered compound form is achieved by dissolving or suspending the compound in an oil vehicle.
- injectable depot forms are made by forming microencapsule matrices of compounds from biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoester) and poly(anhydride). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions compatible with body tissue.
- compositions for rectal or vaginal administration are, for example, suppositories which may be prepared by mixing a compound of the present invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or suppository wax, which suppositories are solid at room temperature. However, it is liquid at body temperature and thus melts in the rectum or vaginal cavity to release the active compound.
- a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or suppository wax
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) a filler or bulking agent such as starch, lactose, sucrose, Glucose, mannitol, and silicic acid, b) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrants such as agar, calcium deoxidized , Potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as cetyl alcohol and glycerol monoste
- Solid compositions of a similar type can also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose as well as high molecular weight polyethylene glycols and the like.
- Tablets, dragees, capsules, pills, and granules in solid dosage form can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation art. It may optionally contain an opacifying agent, and may also be a composition that releases only the active ingredient(s), for example in certain parts of the intestine, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- Solid compositions of a similar type can also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose as well as high molecular weight polyethylene glycols and the like.
- the active compound may also be in micro-encapsulated form with one or more excipients as described above.
- Tablets, dragees, capsules, pills, and granules in solid dosage form can be prepared with coatings and shells such as enteric coatings, controlled release coatings and other coatings well known in the pharmaceutical formulation art.
- the active compound may be mixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may also contain, as in normal practice, additional substances other than inert diluents, such as tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose.
- the dosage form may also contain a buffering agent.
- It may optionally contain opacifying agents and may also be a composition that releases only the active ingredient(s), for example in certain parts of the intestine, optionally, in a delayed manner.
- opacifying agents include polymeric substances and waxes.
- Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- the active ingredient is mixed, as required, under sterile conditions with a pharmaceutically acceptable carrier and any necessary preservatives or buffers.
- Ophthalmic formulations, ear drops, and eye drops are also contemplated as being within the scope of the present invention.
- the present invention contemplates the use of transdermal patches with the added advantage of providing controlled cleavage of the compound into the body.
- Such dosage forms can be made by dissolving or dispersing the compound in an appropriate medium.
- Absorption enhancers can also be used to increase the flow of the compound across the skin. The rate can be controlled by providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- a compound of the present invention or a pharmaceutical composition thereof is administered with an anticancer agent.
- an anticancer agent refers to any agent administered to a subject having cancer to treat cancer.
- Combination therapy involves administering the therapeutic agents concomitantly or sequentially.
- the therapeutic agent can be combined in one composition to be administered to the subject.
- the compounds of the present invention are used in combination with other therapeutic agents.
- the compounds of the present invention may be administered together with a therapeutic agent selected from the group consisting of cytotoxic drugs, radiotherapy, and immunotherapy.
- Additional agents may be administered separately from combination therapy provided as part of a multiple dose therapy.
- the formulations may be part of a single dosage form mixed with a compound of the present invention. If administered as part of a combination therapy, the two therapeutic agents can be given simultaneously, sequentially, or intermittently.
- Combination therapy can be used for any of the therapeutic indications described herein.
- the combination therapy is for treating a proliferative disorder (eg, cancer) in a subject.
- Another aspect of the present invention relates to inhibiting the aforementioned disease in a biological sample or subject, wherein the method comprises administering a compound represented by Formula 1, or a composition comprising the compound, or contacting the biological sample thereto.
- biological sample generally includes in vivo, in vitro, and ex vivo materials, and also includes, but is not limited to, cell culture or extracts thereof; Biopsied substances obtained from mammals or extracts thereof; And blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
- the present inventors confirmed through an experiment that the compound according to the present invention or a pharmaceutically acceptable salt thereof has a useful effect in the prevention or treatment of cancer, degenerative brain disease, non-alcoholic fatty liver disease, influenza, and the like in the present invention.
- the compound according to the present invention as a result of evaluating the fibrosis inhibitory activity, which is a symptom of non-alcoholic steatohepatitis, targeting human liver cancer cell lines as in Experimental Examples 8 and 9, excellent anti-fibrosis effect was confirmed, and the following experiment As shown in Example 10, it was confirmed that the evaluation index for non-alcoholic steatohepatitis induced by the MCD diet was improved, and the compounds of the present invention were found to be useful for the prevention or treatment of non-alcoholic fatty liver disease.
- the compounds of the present invention may be prepared by the following synthesis methods 1 to 3 as an example.
- the reaction may be proceeded after substituting the halogen atom (X) on the pyridine ring in the preparation step of compound B, and further proceeding with the step of removing the halogen atom (X) after completion of the reaction.
- the halogen atom (X) may not be removed.
- reaction may be carried out without replacing the halogen atom (X) in the pyridine ring.
- the compound of Example 1 may be prepared according to Synthesis Method 1, specifically by a reaction as shown in Scheme 1 below.
- Example 7 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)methanesulfonamide
- Example 8 N-(4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)methanesulfonamide
- Example 12 (S)-N-(3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)methanesulfonamide
- Example 17 3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-chlorobenzenesulfonamide
- Example 54 (S)-(3-(3-(6-chloro-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)(morpholino)methanone
- Example 55 was synthesized based on the representative synthesis method 2 above.
- Example 60 (S)-3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-((dimethylamino)methyl)benzamide
- Example 62 (S)-4-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-(2-(dimethylamino)ethyl)benzamide
- Example 64 (S)-N-(3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)-2-(dimethylamino)acetamide
- Example 65 (S)-N-(3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)-2-(4-methylpiperazin-1-yl)acetamide
- Example 66 (S)-N-(3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)-2-morpholinoacetamide
- Example 68 (S)-(3-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)phenyl)(4-methylpiperazin-1-yl)methanone
- Example 70 (S)-4-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-(2-morpholinoethyl)benzamide
- Example 72 (S)-4-(3-(6-bromo-7-((1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)benzamide
- Example 73 N-(4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)-2-(dimethylamino)acetamide
- Example 74 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-2-(dimethylamino)acetamide
- Example 75 N-(4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)-2-(4-methylpiperazin-1-yl)acetamide
- Example 76 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-2-(4-methylpiperazin-1-yl)acetamide
- Example 77 N-(4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)-2-morpholinoacetamide
- Example 78 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-2-morpholinoacetamide
- Example 79 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)-3-(dimethylamino)propanamide
- Example 80 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-3-(dimethylamino)propanamide
- Example 81 (3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)(4-methylpiperazin-1-yl)methanone
- Example 82 3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-(2-(dimethylamino)ethyl)-2-methylbenzamide
- Example 83 (3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)(morpholino)methanone
- Example 84 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)-2-(dimethylamino)acetamide
- Example 85 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)-2-morpholinoacetamide
- Example 86 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4] ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)-3-(dimethylamino)propanamide
- Example 87 N-(3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4 ,5-b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-2-methylphenyl)-2-(4-methylpiperazin-1-yl)acetamide
- Example 88 N-(3-(3-(6-bromo-7-((3-sulfamoylphenyl)amino)-1H-imidazo[4,5-b]pyridin-2-yl)-2 ,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-2-morpholinoacetamide
- Example 90 N-(3-(3-(6-bromo-7-((3-sulfamoylphenyl)amino)-1H-imidazo[4,5-b]pyridin-2-yl)-2 ,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)-2-(dimethylamino)acetamide
- Example 91 (3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)(morpholino)methanone
- Example 92 (3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-4-methylphenyl)(4-methylpiperazin-1-yl)methanone
- Example 93 3-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-1H-imidazo[4,5- b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-N-(2-(dimethylamino)ethyl)-4-methylbenzamide
- Example 96 3-(3-(6-bromo-7-((3-sulfamoylphenyl)amino)-1H-imidazo[4,5-b]pyridin-2-yl)-2,5- Dimethyl-1H-pyrrol-1-yl)-N-(2-(dimethylamino)ethyl)-4-methylbenzamide
- Example 97 (4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)(4-methylpiperazin-1-yl)methanone
- Example 98 (4-(3-(6-bromo-7-(((S)-1-(ethylsulfonyl)pyrrolidin-3-yl)amino)-3H-imidazo[4,5 -b]pyridin-2-yl)-2,5-dimethyl-1H-pyrrol-1-yl)-3-methylphenyl)(morpholino)methanone
- the MLK1 kinase protein and compound were added to a buffer system containing 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2 mg/mL casein, 10 mM Magnesium acetate, and [ ⁇ - 33 P]-ATP, followed by Mg/
- the reaction was initiated by addition of the ATP mixture. After incubation at room temperature for 40 minutes, 0.5% phosphoric acid was added to terminate the reaction. 10 ⁇ L of the reaction mixture was spotted on a P30 filtermat, and washed 4 times in 0.425% phosphoric acid for a total of 4 minutes. After washing once with methanol, the filter mat was dried and scintillation was measured.
- MLK2 kinase protein and compound were added to a buffer system containing 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM Magnesium acetate and [ ⁇ - 33 P]-ATP, and then to the system.
- the reaction was initiated by addition of the Mg/ATP mixture. After incubation at room temperature for 40 minutes, 0.5% phosphoric acid was added to terminate the reaction. 10 ⁇ L of the reaction mixture was spotted on a P30 filter mat, and washed 4 times in 0.425% phosphoric acid for a total of 4 minutes. After washing once with methanol, the filter mat was dried and scintillation was measured.
- MLK3 kinase protein and compound were added to a buffer system containing 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 5 mM DTT, 10 mM Magnesium acetate and [ ⁇ - 33 P]-ATP, and then , Mg/ATP mixture was added to the system to initiate the reaction. After incubation at room temperature for 120 minutes, 0.5% phosphoric acid was added to terminate the reaction. 10 ⁇ L of the reaction mixture was spotted on a P30 filter mat, and washed 4 times in 0.425% phosphoric acid for a total of 4 minutes. After washing once with methanol, the filter mat was dried and scintillation was measured.
- Example IC 50 (nM) Example IC 50 (nM) MLK3 MLK2 MLK1 MLK3 MLK2 MLK1 One 4 N.T. N.T. 52 324 N.T. 87 2 4 N.T. N.T. 53 23181 N.T. 10561 3 5 N.T. N.T. 54 136 N.T. 84 4 13 N.T. 56 55 5922 N.T. 4655 5 6 92 47 56 122 N.T. N.T. 6 6 181 34 57 97 N.T. N.T. 7 6 N.T. 44 58 53 N.T. N.T. 8 7 N.T. N.T. 59 19 N.T. N.T. 9 10 N.T. N.T.
- the compound of Formula 1 according to the present invention has an excellent inhibitory effect on the MLK family, particularly MLK3.
- the compound of Example 7 was treated at a concentration of 3 ⁇ M, and the subsignal transduction proteins of MLK3, MKK3, p38, and The phosphorylation pattern of paxillin was confirmed by Western blot, and is shown in FIG. 1.
- the cell line was spread on a 6-well plate at 40,000 cells/well, and after 24 hours, the compound of Example 7 was treated and cultured for 60 hours. Subsequently, the cultured cells were lysed by adding Pierce's protease inhibitor cocktail (cat.no. 88666) and phosphatase inhibitor cocktail (cat no. A32957) to Protein extraction solution (RIPA buffer; Elpis Biotech), a lysis buffer, and centrifuged. Separation (14,000 rpm) was performed at 4° C. for 15 minutes to obtain pure protein remaining in the upper layer.
- Pierce's protease inhibitor cocktail catalog.no. 88666
- phosphatase inhibitor cocktail cat no. A32957
- Protein is quantified using a BCA protein quantification kit (Bio-Rad), and the same amount of protein is mixed in a sample buffer (Elpis Biotech), heated at 100°C for 10 minutes, and separated on a 10% SDS-polyacrylamide gel. I did. The subsequent process was based on a basic Western blot experiment method, and the separated protein was transferred to a PVDF membrane (Amersham Biosciences), and the protein expression level was confirmed using Atto's chemiluminescence imaging system using antibodies and millipore's ECL.
- Anti-MKK3 8535
- anti-p38 (9212) anti-phospho-p38 (9211), anti-paxillin (2542), anti-phospho- It is paxillin(2541).
- the compound of the embodiment according to the present invention exhibits an effect of inhibiting the activity of the MLK3 sub-protein by inhibiting the phosphorylation of the sub-signal transduction proteins of MLK3 and MLK3.
- human breast cancer cell line MDA-MB-231 colon cancer cell line HT-29, acute myeloid leukemia cell line U937, and chronic myelogenous leukemia cell line K562 were used.
- the cell line was cultured using RPMI-1640 medium containing 10% fetal bovine serum.
- the medium was manufactured by welgene, and the fetal bovine serum was used by hyclone, and the culture medium was used to contain 1% of Gibco's cell culture antibiotic.
- Each cell was laid so as to be 2,000 cells/well in a 96-well plate, and after 24 hours, 10 ⁇ M of each of the compounds according to the examples was treated.
- the compound used was prepared with 10 mM DMSO, diluted with a medium to a final concentration of 10 ⁇ M, and the final concentration of DMSO was 0.1%.
- anticancer activity was measured using CCK-8 (Dojindo).
- the measurement method followed the experimental method presented by the product, and the absorbance at 450 nm wavelength was measured with a microplate reader (Hidex) to confirm the presence or absence of anticancer activity of the compound.
- the absorbance of the well containing no cells is calculated as '0' and the absorbance of the negative control without compound treatment is calculated as '100'
- the relative% average value is reported as the cell activity value
- (100-cell activity value)% was expressed as an anticancer activity value to evaluate the degree of inhibition of cell activity compared to the negative control group.
- the anticancer activity value was 50% or more, it was indicated as'+++', when it was more than 10% and less than 50%, it was indicated as'++', and when it was less than 10%, it was indicated as'+'.
- Example Cancer cell proliferation inhibitory activity MDAMB231 U937 HT29 K562
- the compounds of the examples according to the present invention exhibit an inhibitory effect on cell activity of cancer cells (cancer cell killing effect) against cancer cell lines MDA-MB-231, HT-29, U937, and K562 cell lines.
- acute myeloid leukemia cell line U937 acute lymphoblastic leukemia cell line Jurkat
- gastric cancer cell lines AGS, Hs76T gastric cancer cell lines AGS, Hs76T
- human lung cancer cell line A549 were utilized.
- the cell line was cultured using RPMI-1640 medium (U937, Jurkat, AGS, A549) or DMEM (Hs746T) medium containing 10% fetal bovine serum.
- the medium was manufactured by welgene, and the fetal bovine serum was used by hyclone, and the culture medium was used to contain 1% of Gibco's cell culture antibiotic.
- Each cell was laid so as to be 2,000 cells/well in a 96-well plate, and after 24 hours, 10 ⁇ M of each of the compounds according to the examples was treated.
- the compound used was prepared with 10 mM DMSO, diluted with a medium to a final concentration of 10 ⁇ M, and the final concentration of DMSO was 0.1%.
- anticancer activity was measured using CCK-8 (Dojindo).
- the measurement method followed the experimental method presented by the product, and the absorbance at 450 nm wavelength was measured with a microplate reader (Hidex) to confirm the presence or absence of anticancer activity of the compound.
- the absorbance of the well containing no cells is calculated as '0' and the absorbance of the negative control without compound treatment is calculated as '100'
- the relative% average value is reported as the cell activity value
- (100-cell activity value)% was expressed as an anticancer activity value to evaluate the degree of inhibition of cell activity compared to the negative control group.
- the anticancer activity value was 50% or more, it was indicated as'+++', when it was more than 10% and less than 50%, it was indicated as'++', and when it was less than 10%, it was indicated as'+'.
- the part marked "N.T.” means "Not Tested".
- Example Cancer cell proliferation inhibitory activity U937 Jurkat AGS Hs746T A549
- N.T. 26 ++ ++ ++ ++ ++ N.T. N.T. 27 + + ++ N.T. N.T. 28 + ++ ++ N.T. N.T. 29 + ++ ++ N.T. N.T. 30 + ++ ++ ++ N.T. N.T. 31 ++ ++ ++ N.T. N.T. 32 ++ ++ ++ N.T. N.T. 33 + ++ ++ N.T. N.T. 34 ++ ++ ++ N.T. N.T. 35 ++ ++ ++ ++ N.T. N.T. 36 + + + N.T. N.T. 37 ++ ++ N.T. N.T. 38 ++ +++ +++ +++ +++ +++ +++ +++ +
- the compounds of the examples according to the present invention exhibit an inhibitory effect on cell activity of cancer cells (cancer cell killing effect) against cancer cell lines U937, Jurkat, AGS, Hs746T, and A549 cell lines.
- the compound of Example 7 was 0.1, 0.3, 1, 3, 10, 30 using the human breast cancer cell line MDA-MB-231 and the acute T cell leukemia cell line Jurkat.
- the anticancer activity was evaluated in the same manner as in Experimental Example 3 by treatment with a concentration of ⁇ M, and the concentration of 50% inhibition was calculated using an Excel program and expressed as an IC 50 value.
- the compounds of the examples according to the present invention exhibit excellent cancer cell activity inhibition (cancer cell killing effect) at a concentration in micromolar units with respect to cancer cell lines MDA-MB-231 and Jurkat cell lines.
- the compound of the example was treated at a concentration of 0.1, 0.3, 1, 3, 10, 30 ⁇ M, respectively, and the same as in Experimental Example 3
- the anticancer activity was evaluated by the method, and the 50% inhibitory concentration was calculated using an Excel program and expressed as an IC 50 value.
- the part marked with "NT” means "Not Tested”.
- Example IC 50 ( ⁇ M) Example IC 50 ( ⁇ M)
- Example IC 50 ( ⁇ M) Example IC 50 ( ⁇ M)
- Example IC 50 ( ⁇ M) Example IC 50 ( ⁇ M) 7 7.4 60 5.56 73 5.42 86 4.82 8 3.4 61 5.32 74 6.12 87 5.71 9 3.69 62 5.53 75 6.23 88 7.72 50 N.T. 63 5.28 76 7 89 >10 51 >10 64 4.09 77 >10 90 >10 52 >10 65 2.71 78 7.33 91 6.7 53 N.T. 66 5.19 79 3.06 92 8.65 54 6.78 67 >10 80 6.51 93 6.76 55 N.T. 68 N.T. 81 >10 94 5.96 56 5.63 69 N.T. 82 5.97 95 >10 57 5.49 70 N.T. 83 8.59 96 >10 58 N.T. 71 N.T. 84 5.85 97 >10 59 N.T. 72 9.28 85 >10
- the compounds of the examples according to the present invention exhibit excellent cancer cell activity inhibition (cancer cell killing effect) at a concentration in micromolar units with respect to the Hs746T cell line, which is a cancer cell line.
- the human breast cancer cell line MDA-MB-231 was used. After culturing for 24 hours at 15,000 cells/well in an ImageLock 96-well plate (Essen BioScience), it was replaced with a serum-free medium. Using a 96-well Wound maker (Essen BioScience), cells were uniformly scraped for each well to form a wound, and the compounds were treated at a concentration of 1 or 3 ⁇ M, respectively, and Wound was performed every 12 hours using IncuCyte software. The remaining distance of was measured. All experiments were repeated three times, and FIG. 3 is a photograph showing the results of 60 hours after Wound formation.
- the compound of the embodiment according to the present invention exhibits excellent cancer metastasis inhibitory effect at a concentration in micromolar units with respect to the cancer cell line MDA-MB-231.
- the human liver cancer cell line HepG2 was purchased and used from ATCC.
- the cell line was cultured in 5% CO 2 , 37°C environment using DMEM (Dulbecco's modification of Eagle's medium) to which Gibco's FBS (Fetal Bovine Serum) 10%, penicillin 100 U/mL, and streptomycin 100 ⁇ g/mL were added. I did.
- Palmitic acid (sigma) was used to induce fibrosis.
- DPBS Dynamic Phosphate-Buffered Saline
- 20mM of palmitic acid and 0.001N of NaOH is mixed with 20mM of palmitic acid and 0.001N of NaOH, and maintained at 70°C for 30 minutes to make a suspension, and then mixed with 5% fatty acid free BSA solution in a 1:3 ratio (5mM). It was conjugated to °C.
- the group that did not induce fibrosis by treatment with palmitic acid was set as the non-inducing group, and the group treated with palmitic acid was set as the negative control group, and the group treated with palmitic acid and the compound was set as the experimental group.
- Real-time PCR was performed according to the method recommended by the manufacturer using the power SYBR green PCR master mix (Applied Biosystem), and relative gene expression values were quantitatively expressed based on the house keeping gene, ⁇ -actin.
- the compounds of the examples according to the present invention inhibit the expression of the fibrosis marker gene induced by palmitic acid in the liver cancer cell line HepG2, through which the antifibrotic effect of the compounds according to the present invention I can confirm.
- the human liver cancer cell line HepG2 was purchased and used from ATCC to confirm the preventive and therapeutic effect of the compound in non-alcoholic steatohepatitis.
- the cell line was cultured in a 5% CO 2 , 37°C environment using DMEM (Dulbecco's modification of Eagle's medium) to which Gibco's FBS (Fetal Bovine Serum) 10%, penicillin 100 U/mL, and streptomycin 100 ⁇ g/mL were added. I did.
- Palmitic acid (sigma) was used to induce fibrosis.
- Dulbecco's Phosphate-Buffered Saline (DPBS) is mixed with 20 mM of palmitic acid and 0.001 N of NaOH, and maintained at 70° C. for 30 minutes to make a suspension, and then mixed with 5% fatty acid free BSA solution in a 1:3 ratio (5 mM). It was conjugated to °C.
- DPBS Dulbecco's Phosphate-Buffered Saline
- the group that did not induce fibrosis by treatment with palmitic acid was set as the non-inducing group, and the group treated with palmitic acid was set as the negative control group, and the group treated with palmitic acid and the compound was set as the test group.
- the compounds of the examples according to the present invention inhibit the expression of the fibrosis marker gene induced by palmitic acid in the liver cancer cell line HepG2, through which the antifibrotic effect of the compound according to the present invention I can confirm.
- an animal model of non-alcoholic steatohepatitis fed a methionine- and choline-deficient (MCD) diet to 6-week-old C57BL/6J mice was used.
- the normal diet group was fed a normal diet (Chow) autonomously, and the MCD group was induced to a non-alcoholic steatohepatitis model through 8 weeks of voluntarily feeding the MCD diet (Molecules 2014, 19, 8189-8211). Animals were reared in a well-ventilated environmental condition maintained at a temperature of 23 ⁇ 2°C and a relative humidity of 55 ⁇ 5%. Fluorescent lighting was provided for about 12 hours per day, and litter was changed once a week.
- the MCD-fed animals Eight weeks after the normal diet or MCD diet, the MCD-fed animals were administered the drug intraperitoneally once a day for 4 weeks. At this time, all animals maintained the existing diet. Of the MCD-fed animals, the "experimental group” was administered 10 mg/kg of the compound of Example 7, and the “negative control group” was administered intraperitoneally once a day for 4 weeks.
- the composition of the animal group of this experimental example is shown in Table 9 below.
- FIGS. 4 to 6 Body weight, feed and drinking water intake are measured once a week, and after 12 weeks of experimentation, serum biochemical indicators (ALT, AST, ALP, TG, Glucose, Albumin) and histopathological indicators (Sirius-Red staining followed by Brunt score evaluation) ) was evaluated, and some of the results are shown in FIGS. 4 to 6.
- serum biochemical indicators ALT, AST, ALP, TG, Glucose, Albumin
- histopathological indicators Sirius-Red staining followed by Brunt score evaluation
- Example compound according to the present invention In order to confirm the inhibitory effect of the Example compound according to the present invention on the LRRK2 wild type and the mutant (G2019S) kinase of LRRK2, BL21-derived E. coli bacteria from a 24-well plate to the log phase. After incubation, MOI (Multiplicity of infection) was infected with 0.4 using T7 phage tagged with LRRK2 wild type or LRRK2 mutation (G2019S). Then, the E. coli bacteria were stirred at 32° C. for 90 to 150 minutes to allow dissolution. The lysate of E.
- MOI Multiplicity of infection
- coli bacteria was centrifuged (6,000 xg) and filtered (0.2 um) to transfect the obtained tagged T7 phage into HEK293 cells, and a DNA-tagged kinase protein (LRRK2 or LRRK2 G2019S) was obtained.
- Streptavidin-coated magnetic beads were treated with a biotinylated low-molecular ligand at room temperature for 30 minutes to prepare an affinity resin.
- the biotinylated ligand was blocked with excess biotin and washed with Pierce's buffer SeaBlock (1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and reduce non-specific binding. I did.
- the binding reaction was performed by mixing an affinity bead in which a kinase and a ligand were bound obtained from HEK293 cells, and an Example compound contained in 1X buffer.
- the compound was prepared in 100% DMSO at a concentration of 40X, diluted and used, and all binding reactions were performed in a 384-well plate at a final volume of 0.02 ml. After stirring the plate for 1 hour at room temperature, affinity beads were washed with washing buffer (1x PBS, 0.05% Tween 20), and elution (elution) buffer (1x PBS, 0.05% Tween 20, 0.5 ⁇ M non-biotinylated affinity ligand) ) To resuspension.
- Example 12 100 17.0 4.0 500 3.5 0.8 Example 3 100 17.0 3.5 500 3.1 0.9 Example 7 100 2.9 2.3 500 0.4 1.5 Example 11 100 28.0 7.9 500 6.9 1.7
- Example 12 100 16.0 3.6 500 3.7 0.5 Example 25 100 49.0 15.0 500 17.0 3.3
- Example 54 100 24.0 6.3 500 4.1 0.4
- Example 58 100 5.0 1.4 500 0.7 0.2
- Example 76 100 3.6 0.9 500 1.1 0.1
- Example 81 100 0.7 0.0 500 0.6 0.1
- Example 88 100 73.0 57.0 500 46.0 19.0
- Example 93 100 60.0 66.0 500 51.0 25.0
- Example 94 100 70.0 59.0 500 40.0 16.0
- Example 95 100 68.0 79.0 500 43.0 24.0
- Example 96 100 0.4 0.8 500 0.0 0.6
- Example 98 100 18.0 8.2 500 3.5 1.0
- an NIH-3T3 cell line known as an LRRK2 expressing cell line was used, and a DMEM medium containing 10% of Gibco's FBS and 1% of Penicillin/Streptomycin was used. Using, 5% CO 2 , cultured in an environment at 37°C.
- Example 7 and LRRK2 inhibitors HG-10-102-01 and GNE0877 (comparative compounds 1 and 2, respectively), MLK inhibitor CEP1347 (comparative compound) 3) were treated at concentrations of 5, 20, 100, and 1000 nM, respectively.
- MLK inhibitor CEP1347 (comparative compound) 3 were treated at concentrations of 5, 20, 100, and 1000 nM, respectively.
- a protein was obtained using Lysis buffer (50 mM Tris-HCl (pH7.5), 0.5% TX-100, 150 mM NaCl, 0.5 mM EDTA, Protease inhibitor mixture, 0.2 mM PMSF). The obtained protein was quantified using the Thermo Fisher Scientific's BCA kit, and after heating at 75° C.
- Example compound according to the present invention inhibits LRRK2 phosphorylation at a level similar to that of Comparative Compounds 1 and 2, which are LRRK2 inhibitors, in the NIH-3T3 cell line, which is an LRRK2 expressing cell line.
- the fetus was isolated from a rat 15-day pregnant, and then the cerebral cortical region was excised and used as a primary cortical neuron. After dispensing into a 12-well plate at 2 ⁇ 10 5 cells and incubating for 24 hours, the cells were replaced with Gibco's Neurobasal medium and cultured. On the 11th day in vitro, LRRK2 G22019S was transformed using Invitrogen's Lipofectamine and Opti-MEM, and 6 hours later, the example compound or the comparative compound was treated at a concentration of 0.01, 0.1, and 1 ⁇ M.
- the compound of the example according to the present invention protects in a dose-dependent manner against neuronal damage caused by overexpression of the LRRK2 G2019S mutation.
- the MDCK cell line sufficiently grown in a 96-well plate was washed with phosphate-buffered saline (PBS), followed by 50-100 plaque forming units (PFU). ) Of influenza virus was inoculated for each well. The virus was allowed to stand at 35° C. for about 1 hour to infect cells. After removing the culture solution and washing with phosphate buffered saline, 2 ⁇ g/ml TPCK-trypsin-containing MEM culture solution in which each example compound was diluted at various concentrations was added to each well. On the third day after infection, cell activity was evaluated using MTT (Sigma) [Jang YJ et. al., (2014). Antiviral Res 107:66-75.]. By measuring the absorbance at 540 nm and 690 nm wavelength, 50% cytotoxic concentration (CC 50 ) and 50% effective concentration (EC 50 ) were calculated.
- PBS phosphate-buffered saline
- PFU plaque forming units
- the compounds of Examples according to the present invention exhibit an effect of inhibiting cytotoxicity (antiviral effect) due to viral infection at a micromolar concentration with respect to the MDCK cell line infected with the influenza virus.
- the A549 cell line a human lung cancer cell line sufficiently grown in a 24-well plate, was washed with phosphate-buffered saline (PBS), and then 14,000 plaque-forming units (plaque) were washed in each well.
- PBS phosphate-buffered saline
- plaque plaque-forming units
- PFU forming units
- TPCK-trypsin-containing RPMI culture solution in which each Example compound was diluted to a concentration of 11, 33, and 100 ⁇ M was added to each well and cultured at 35°C.
- each cell culture medium was collected after 2 days of culture, diluted 10 times from 10 -1 to 10 -8 , and infected with MDCK cells grown 100% in a 96-well plate.
- cell activity was measured using MTT (Sigma), and 50% endpoint was calculated using Reed-Muench or Spearman-Karber method. This is expressed as TCID50/ml (tissue culture infective dose 50%), which is a unit expressed as a titer of the dilution factor at which the virus-inoculated cells are infected by 50%.
- TCID50/ml tissue culture infective dose 50%
- the negative control group infected the virus, but was not treated with the example compound.
- a mouse model infected with a mouse-adapted PR8 (hereinafter referred to as "maPR8") virus was used.
- the model was established by infecting 7-week-old Balb/c mice with a virus corresponding to a titer of 3 MLD 50 (half lethal dose to a mouse) through the nasal route.
- the compound of Example 4 was intraperitoneally administered one day before virus infection (day 0).
- the experimental group (Example 4 compound) was administered once a day at a concentration of 10 mg/kg/day for 9 days.
- mice Three mice were used per group, and the antiviral efficacy was measured by measuring body weight, and individuals with a weight loss of more than 30% from the start of the experiment were euthanized (based on the regulations of the Animal Testing Committee of the Research Institute of Chemical Technology). Ha) [Shin JS et. al., (2017) J Microbiol. 55:979-983].
- the animal group administered the compound of the embodiment according to the present invention normalizes the body weight of the mouse model infected with the influenza virus and increases the survival rate.
Abstract
Description
실시예 | IC50(nM) | 실시예 | IC50(nM) | ||||
MLK3 | MLK2 | MLK1 | MLK3 | MLK2 | MLK1 | ||
1 | 4 | N.T. | N.T. | 52 | 324 | N.T. | 87 |
2 | 4 | N.T. | N.T. | 53 | 23181 | N.T. | 10561 |
3 | 5 | N.T. | N.T. | 54 | 136 | N.T. | 84 |
4 | 13 | N.T. | 56 | 55 | 5922 | N.T. | 4655 |
5 | 6 | 92 | 47 | 56 | 122 | N.T. | N.T. |
6 | 6 | 181 | 34 | 57 | 97 | N.T. | N.T. |
7 | 6 | N.T. | 44 | 58 | 53 | N.T. | N.T. |
8 | 7 | N.T. | N.T. | 59 | 19 | N.T. | N.T. |
9 | 10 | N.T. | N.T. | 60 | 27 | N.T. | 24 |
10 | 7 | N.T. | N.T. | 61 | 30 | N.T. | 19 |
11 | 7 | N.T. | N.T. | 62 | 17 | N.T. | 22 |
12 | 7 | 65 | 52 | 63 | 14 | N.T. | 22 |
13 | 7 | N.T. | N.T. | 64 | 14 | N.T. | 34 |
14 | 17 | N.T. | N.T. | 65 | 26 | N.T. | 42 |
15 | 34 | N.T. | N.T. | 66 | 17 | N.T. | 22 |
16 | 11 | N.T. | N.T. | 67 | 19 | N.T. | 32 |
17 | 12 | N.T. | N.T. | 68 | 16 | N.T. | 25 |
18 | 13 | 109 | 75 | 69 | 13 | N.T. | 22 |
19 | 14 | 90 | 36 | 70 | 18 | N.T. | 36 |
20 | 14 | 217 | 31 | 71 | 26 | N.T. | 36 |
21 | 15 | 243 | 75 | 72 | 15 | N.T. | 25 |
22 | 17 | 186 | 38 | 73 | 25 | N.T. | 25 |
23 | 17 | 56 | 25 | 74 | 46 | N.T. | 43 |
24 | 20 | 95 | 29 | 75 | 16 | N.T. | 30 |
25 | 26 | 250 | 71 | 76 | 63 | N.T. | 64 |
26 | 19 | N.T. | N.T. | 77 | 7 | N.T. | 19 |
27 | 20 | 178 | 176 | 78 | 47 | N.T. | 25 |
28 | 57 | N.T. | N.T. | 79 | 7 | N.T. | 35 |
29 | 25 | N.T. | N.T. | 80 | 33 | N.T. | 33 |
31 | 35 | N.T. | N.T. | 81 | 9 | N.T. | 14 |
32 | 32 | N.T. | N.T. | 82 | 14 | N.T. | 34 |
33 | 38 | N.T. | N.T. | 83 | 12 | N.T. | 22 |
34 | 41 | N.T. | N.T. | 84 | 8 | N.T. | 16 |
35 | 46 | N.T. | N.T. | 85 | 11 | N.T. | 14 |
36 | 46 | N.T. | N.T. | 86 | 7 | N.T. | 15 |
37 | 47 | N.T. | N.T. | 87 | 13 | N.T. | 24 |
38 | 52 | N.T. | N.T. | 88 | 52 | N.T. | 82 |
39 | 72 | N.T. | N.T. | 89 | 81 | N.T. | 169 |
40 | 68 | N.T. | N.T. | 90 | 92 | N.T. | 160 |
41 | 70 | N.T. | N.T. | 91 | 25 | N.T. | 19 |
42 | 83 | N.T. | N.T. | 92 | 26 | N.T. | 15 |
43 | 85 | N.T. | N.T. | 93 | 54 | N.T. | 33 |
44 | 27 | 211 | 109 | 94 | 73 | N.T. | 52 |
45 | 32 | 524 | 85 | 95 | 60 | N.T. | 37 |
49 | 15 | N.T. | 50 | 96 | 137 | N.T. | 145 |
50 | >30,000 | N.T. | >30,000 | 97 | 20 | N.T. | 14 |
51 | 330 | N.T. | 53 | 98 | 14 | N.T. | 14 |
실시예 | 암세포 증식억제활성 | |||
MDAMB231 | U937 | HT29 | K562 | |
1 | ++ | ++ | ++ | + |
2 | +++ | +++ | +++ | +++ |
3 | +++ | +++ | ++ | +++ |
4 | ++ | +++ | +++ | +++ |
7 | ++ | +++ | ++ | +++ |
13 | ++ | +++ | ++ | ++ |
14 | + | ++ | ++ | + |
15 | +++ | ++ | + | ++ |
16 | ++ | +++ | ++ | +++ |
26 | ++ | ++ | ++ | + |
31 | + | ++ | +++ | ++ |
33 | ++ | ++ | + | + |
35 | ++ | ++ | +++ | + |
37 | +++ | ++ | +++ | + |
38 | ++ | +++ | +++ | +++ |
39 | ++ | + | ++ | ++ |
40 | ++ | +++ | +++ | ++ |
실시예 | 암세포 증식억제활성 | ||||
U937 | Jurkat | AGS | Hs746T | A549 | |
1 | ++ | ++ | ++ | N.T. | N.T. |
2 | ++ | ++ | +++ | N.T. | N.T. |
3 | ++ | +++ | N.T. | +++ | ++ |
4 | +++ | +++ | +++ | N.T. | N.T. |
5 | ++ | ++ | +++ | N.T. | N.T. |
6 | ++ | +++ | +++ | N.T. | N.T. |
7 | +++ | +++ | +++ | N.T. | N.T. |
8 | +++ | +++ | +++ | +++ | +++ |
9 | +++ | +++ | +++ | +++ | +++ |
10 | ++ | +++ | ++ | N.T. | N.T. |
11 | ++ | +++ | +++ | N.T. | N.T. |
12 | ++ | ++ | +++ | N.T. | N.T. |
13 | ++ | +++ | +++ | N.T. | N.T. |
14 | ++ | ++ | ++ | N.T. | N.T. |
15 | ++ | + | ++ | N.T. | N.T. |
16 | + | ++ | ++ | N.T. | N.T. |
17 | ++ | +++ | +++ | N.T. | N.T. |
18 | N.T. | N.T. | +++ | ++ | ++ |
19 | +++ | +++ | +++ | N.T. | N.T. |
20 | + | ++ | ++ | N.T. | N.T. |
21 | ++ | ++ | +++ | N.T. | N.T. |
22 | N.T. | N.T. | ++ | N.T. | N.T. |
23 | ++ | +++ | ++ | N.T. | N.T. |
24 | ++ | ++ | ++ | N.T. | N.T. |
25 | ++ | +++ | +++ | N.T. | N.T. |
26 | ++ | ++ | ++ | N.T. | N.T. |
27 | + | + | ++ | N.T. | N.T. |
28 | + | ++ | ++ | N.T. | N.T. |
29 | + | ++ | ++ | N.T. | N.T. |
30 | + | ++ | ++ | N.T. | N.T. |
31 | ++ | ++ | ++ | N.T. | N.T. |
32 | ++ | ++ | ++ | N.T. | N.T. |
33 | + | ++ | ++ | N.T. | N.T. |
34 | ++ | ++ | ++ | N.T. | N.T. |
35 | ++ | ++ | ++ | N.T. | N.T. |
36 | + | + | + | N.T. | N.T. |
37 | ++ | ++ | ++ | N.T. | N.T. |
38 | ++ | +++ | +++ | N.T. | N.T. |
39 | ++ | +++ | +++ | N.T. | N.T. |
40 | ++ | +++ | ++ | N.T. | N.T. |
41 | ++ | ++ | ++ | N.T. | N.T. |
42 | ++ | +++ | +++ | N.T. | N.T. |
43 | ++ | +++ | ++ | N.T. | N.T. |
44 | ++ | ++ | ++ | N.T. | N.T. |
45 | ++ | + | ++ | N.T. | N.T. |
46 | ++ | +++ | ++ | N.T. | N.T. |
50 | N.T. | N.T. | N.T. | N.T. | N.T. |
51 | +++ | +++ | N.T. | +++ | ++ |
52 | +++ | +++ | N.T. | +++ | ++ |
53 | N.T. | N.T. | N.T. | N.T. | N.T. |
54 | +++ | +++ | N.T. | +++ | +++ |
55 | N.T. | N.T. | N.T. | N.T. | N.T. |
56 | +++ | +++ | +++ | +++ | +++ |
57 | +++ | +++ | +++ | +++ | +++ |
58 | + | + | + | + | + |
59 | ++ | ++ | + | ++ | + |
60 | +++ | +++ | +++ | +++ | +++ |
61 | +++ | +++ | +++ | +++ | +++ |
62 | +++ | +++ | +++ | +++ | +++ |
63 | +++ | +++ | +++ | +++ | +++ |
64 | +++ | +++ | +++ | +++ | +++ |
65 | +++ | +++ | +++ | +++ | + |
66 | ++ | +++ | +++ | +++ | ++ |
67 | +++ | +++ | +++ | ++ | ++ |
68 | +++ | +++ | +++ | +++ | +++ |
69 | +++ | +++ | +++ | ++ | ++ |
70 | +++ | +++ | +++ | ++ | ++ |
71 | ++ | +++ | +++ | +++ | + |
72 | +++ | +++ | +++ | +++ | ++ |
73 | +++ | +++ | +++ | +++ | +++ |
74 | +++ | +++ | +++ | +++ | +++ |
75 | +++ | +++ | +++ | +++ | +++ |
76 | +++ | +++ | +++ | +++ | + |
77 | +++ | +++ | +++ | ++ | ++ |
78 | +++ | +++ | +++ | +++ | +++ |
79 | +++ | +++ | +++ | +++ | +++ |
80 | +++ | +++ | +++ | +++ | +++ |
81 | +++ | +++ | +++ | ++ | ++ |
82 | +++ | +++ | +++ | +++ | +++ |
83 | +++ | +++ | +++ | +++ | ++ |
84 | +++ | +++ | +++ | +++ | +++ |
85 | +++ | +++ | +++ | ++ | ++ |
86 | +++ | +++ | +++ | +++ | +++ |
87 | +++ | +++ | +++ | +++ | +++ |
88 | ++ | +++ | +++ | +++ | ++ |
89 | + | ++ | ++ | ++ | + |
90 | ++ | +++ | +++ | ++ | ++ |
91 | +++ | +++ | +++ | +++ | +++ |
92 | +++ | +++ | +++ | +++ | ++ |
93 | +++ | +++ | +++ | +++ | ++ |
94 | ++ | ++ | ++ | +++ | + |
95 | + | ++ | ++ | ++ | + |
96 | + | + | + | ++ | + |
97 | +++ | +++ | +++ | ++ | +++ |
98 | +++ | +++ | +++ | +++ | ++ |
실시예 | IC50(μM) | 실시예 | IC50(μM) | 실시예 | IC50(μM) | 실시예 | IC50(μM) |
7 | 7.4 | 60 | 5.56 | 73 | 5.42 | 86 | 4.82 |
8 | 3.4 | 61 | 5.32 | 74 | 6.12 | 87 | 5.71 |
9 | 3.69 | 62 | 5.53 | 75 | 6.23 | 88 | 7.72 |
50 | N.T. | 63 | 5.28 | 76 | 7 | 89 | >10 |
51 | >10 | 64 | 4.09 | 77 | >10 | 90 | >10 |
52 | >10 | 65 | 2.71 | 78 | 7.33 | 91 | 6.7 |
53 | N.T. | 66 | 5.19 | 79 | 3.06 | 92 | 8.65 |
54 | 6.78 | 67 | >10 | 80 | 6.51 | 93 | 6.76 |
55 | N.T. | 68 | N.T. | 81 | >10 | 94 | 5.96 |
56 | 5.63 | 69 | N.T. | 82 | 5.97 | 95 | >10 |
57 | 5.49 | 70 | N.T. | 83 | 8.59 | 96 | >10 |
58 | N.T. | 71 | N.T. | 84 | 5.85 | 97 | >10 |
59 | N.T. | 72 | 9.28 | 85 | >10 | 98 | 8.11 |
유전자 | 정방향 프라이머(5'-3') | 역방향 프라이머(5'-3') |
β-actin | GGACTTCGAGCAAGAGATGG(서열번호 1) | AGCACTGTGTTGGCGTACAG(서열번호 2) |
α-SMA | CCGACCGAATGCAGAAG(서열번호 3) | ACAGAGTATTTGCGCTCCGGA(서열번호 4) |
Col1A1 | CGAAGACATCCCACCAATCAC(서열번호 5) | ACAGATCACGTCATCGCACAA(서열번호 6) |
Col6A3 | CTCTACCGAGCCCAGGTGTT(서열번호 7) | ATGAGGGTGCGAACGTACTG(서열번호 8) |
상대적 발현 억제 정도(%) | |||
α-SMA | Col1A1 | Col6A3 | |
비유도군 | 100 | 100 | 100 |
음성대조군 | 0 | 0 | 0 |
실험군(실시예 7) | 73.1 | 200.2 | 116.2 |
유전자 | 정방향 프라이머(5'-3') | 역방향 프라이머(5'-3') |
β-actin | TAGCCATCCAGGCTGTGCTG(서열번호 9) | CAGGATCTTCATGAGGTAGTC(서열번호 10) |
Fibronectin-1 | CCCTATCTCTGAYACCGTTGTCC(서열번호 11) | TGCCGCAACTACTGTGATTCGG(서열번호 12) |
TGF-β1 | TGCTCCAAACCACAGAGTAGGC(서열번호 13) | CCCAGAACACTAAGCCCATTGC(서열번호 14) |
α-SMA | TCAGCGCCTCCAGTTCCT(서열번호 15) | AAAAAAAACCACGAGTAACAAATCAA(서열번호 16) |
상대적 발현 억제 정도(%) | |||
α-SMA | TGF-β1 | Fibronectin-1 | |
비유도군 | 100 | 100 | 100 |
음성대조군 | 0 | 0 | 0 |
실시예 2 | 48.35 | 97.39 | 77.72 |
실시예 3 | ambiguous | 109.05 | 72.85 |
실시예 11 | 24.73 | 99.40 | 86.85 |
실시예 12 | 49.92 | 113.03 | 74.32 |
실시예 36 | 79.46 | 66.72 | 82.94 |
실시예 44 | 73.45 | 57.05 | 75.60 |
실시예 45 | 74.97 | 33.15 | 60.64 |
실시예 53 | 74.74 | 33.15 | 69.92 |
실시예 58 | 66.53 | 48.93 | 69.83 |
실시예 76 | 69.54 | 121.79 | 93.95 |
실시예 81 | 61.69 | 44.28 | 61.05 |
실시예 88 | 74.86 | 56.45 | 86.78 |
실시예 93 | 73.82 | 42.54 | 74.05 |
실시예 95 | 67.81 | 45.25 | 65.78 |
실시예 96 | 37.83 | 92.86 | 61.67 |
식이 (12주) | 투여 용량 (mg/kg) | 투여 시작 | 투여 종료 | |
비유도군 | 정상식이 | 해당없음 | 해당없음 | 해당없음 |
음성대조군 | MCD식이 | 10 | 9주 | 12주 |
실험군 | MCD식이 | 10 | 9주 | 12주 |
화합물 | 농도(nM) | 잔여 활성값(%) | |
LRRK2 | LRRK2(G2019S) | ||
실시예 2 | 100 | 17.0 | 4.0 |
500 | 3.5 | 0.8 | |
실시예 3 | 100 | 17.0 | 3.5 |
500 | 3.1 | 0.9 | |
실시예 7 | 100 | 2.9 | 2.3 |
500 | 0.4 | 1.5 | |
실시예 11 | 100 | 28.0 | 7.9 |
500 | 6.9 | 1.7 | |
실시예 12 | 100 | 16.0 | 3.6 |
500 | 3.7 | 0.5 | |
실시예 25 | 100 | 49.0 | 15.0 |
500 | 17.0 | 3.3 | |
실시예 54 | 100 | 24.0 | 6.3 |
500 | 4.1 | 0.4 | |
실시예 58 | 100 | 5.0 | 1.4 |
500 | 0.7 | 0.2 | |
실시예 76 | 100 | 3.6 | 0.9 |
500 | 1.1 | 0.1 | |
실시예 81 | 100 | 0.7 | 0.0 |
500 | 0.6 | 0.1 | |
실시예 88 | 100 | 73.0 | 57.0 |
500 | 46.0 | 19.0 | |
실시예 93 | 100 | 60.0 | 66.0 |
500 | 51.0 | 25.0 | |
실시예 94 | 100 | 70.0 | 59.0 |
500 | 40.0 | 16.0 | |
실시예 95 | 100 | 68.0 | 79.0 |
500 | 43.0 | 24.0 | |
실시예 96 | 100 | 0.4 | 0.8 |
500 | 0.0 | 0.6 | |
실시예 98 | 100 | 18.0 | 8.2 |
500 | 3.5 | 1.0 |
Toxicity(CC50, μM) | Antiviral activity (EC50, μM) | Selectivity index: CC50/EC50 | |||||
화합물 | Mock | PR8 | HK | LE | PR8 | HK | LE |
실시예 23 | >100 | >100 | 31.6 | >100 | ND | >3.2 | ND |
실시예 12 | >100 | 100 | 27 | >100 | >1.0 | >3.7 | ND |
실시예 7 | >100 | 31.9 | 40 | >100 | >3.1 | >2.5 | ND |
실시예 4 | >100 | 11.1 | 9.8 | 9.9 | >9.0 | >10.2 | >10.1 |
실시예 17 | >100 | 92.9 | 10.8 | >100 | >1.1 | >9.3 | ND |
Claims (16)
- 하기 화학식 1로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염:[화학식 1]상기 식에서,Ar은 C6-C20 아릴 또는 5 내지 20원 헤테로아릴이며,R1, R2 및 R3는 서로 독립적으로, 각각 수소, 할로겐, 히드록시, 시아노, 니트로, -SRa, -S(=O)Ra, -S(=O)2Ra, -NRbRc, -CO2Rb, -CO-NRbRc, C1-C20 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시알킬, C1-C6 아미노알킬, C2-C20 알켄일, C2-C20 알킨일, C1-C8 알콕시, C3-C12 사이클로알킬, C4-C12 사이클로알킬알킬, 3 내지 12원 헤테로사이클릴, 3 내지 12원 헤테로사이클릴알킬, C6-C20 아릴 및 5 내지 20원 헤테로아릴로 이루어진 군에서 선택되며,상기 Ra, Rb 및 Rc는 서로 독립적으로, 각각 수소, 할로겐, 히드록시, 시아노, 니트로, C1-C20 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시알킬, C1-C6 아미노알킬, C2-C20 알켄일, C2-C20 알킨일, C1-C8 알콕시, C3-C12 사이클로알킬, C4-C12 사이클로알킬알킬, 3 내지 12원 헤테로사이클릴, 3 내지 12원 헤테로사이클릴알킬, C6-C20 아릴 및 5 내지 20원 헤테로아릴로 이루어진 군에서 선택되며,상기 l은 0 내지 3의 정수이며, m은 0 내지 3의 정수이고,여기서 상기 알킬, 할로알킬, 하이드록시알킬, 알콕시알킬, 아미노알킬, 알켄일, 알킨일, 알콕시, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴 및 헤테로아릴은 각각 수소, 할로겐, 히드록시, 시아노, 니트로, -SRa, -S(=O)Ra, -S(=O)2Ra, -NRbRc, -CO2Rb, -CO-NRbRc, C1-C10 알킬, C1-C4 할로알킬, C1-C4 하이드록시알킬, C1-C4 알콕시알킬, C1-C4 아미노알킬, C2-C10 알켄일, C2-C10 알킨일, C1-C4 알콕시, C3-C10 사이클로알킬, C4-C10 사이클로알킬알킬, 3 내지 10원 헤테로사이클릴, 3 내지 10원 헤테로사이클릴알킬, C6-C12 아릴 및 5 내지 12원 헤테로아릴로 이루어진 군에서 선택된 하나 이상의 치환기로 치환될 수 있다.
- 제1항에 있어서,하기 화학식 2로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염:[화학식 2]상기 식에서,R1 내지 R3, l 및 m은 상기 화학식 1의 정의와 동일하며,R4는 서로 독립적으로 수소, 할로겐, 히드록시, 시아노, 니트로, -SRa, -S(=O)Ra, -S(=O)2Ra, -NRbRc, -CO2Rb, -CO-NRbRc, C1-C10 알킬, C1-C4 할로알킬, C1-C4 하이드록시알킬, C1-C4 알콕시알킬, C1-C4 아미노알킬, C2-C10 알켄일, C2-C10 알킨일, C1-C4 알콕시, C3-C10 사이클로알킬, C4-C10 사이클로알킬알킬, 3 내지 10원 헤테로사이클릴, 3 내지 10원 헤테로사이클릴알킬, C6-C12 아릴 및 5 내지 12원 헤테로아릴로 이루어진 군에서 선택되거나 이웃한 기끼리 서로 결합하여 고리를 형성할 수 있으며,n은 0 내지 5의 정수이며,여기서 상기 알킬, 할로알킬, 하이드록시알킬, 알콕시알킬, 아미노알킬, 알켄일, 알킨일, 알콕시, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴 및 헤테로아릴은 각각 수소, 할로겐, 히드록시, 시아노, 니트로, -SRa, -S(=O)Ra, -S(=O)2Ra, -NRbRc, -CO2Rb, -CO-NRbRc, C1-C10 알킬, C1-C4 할로알킬, C1-C4 하이드록시알킬, C1-C4 알콕시알킬, C1-C4 아미노알킬, C2-C10 알켄일, C2-C10 알킨일, C1-C4 알콕시, C3-C10 사이클로알킬, C4-C10 사이클로알킬알킬, 3 내지 10원 헤테로사이클릴, 3 내지 10원 헤테로사이클릴알킬, C6-C12 아릴 및 5 내지 12원 헤테로아릴로 이루어진 군에서 선택된 하나 이상의 치환기로 더 치환될 수 있다.
- 제2항에 있어서,하기 화학식 5로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염:[화학식 5]상기 식에서,R1 내지 R4, m 및 n은 상기 화학식 2의 정의와 동일하며,p는 0 내지 2의 정수이며,R5 및 R6은 서로 독립적으로, 각각 수소, 할로겐, 히드록시, 시아노, 니트로, C1-C20 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시알킬, C1-C6 아미노알킬, C2-C20 알켄일, C2-C20 알킨일, C1-C8 알콕시, C3-C12 사이클로알킬, C4-C12 사이클로알킬알킬, 3 내지 12원 헤테로사이클릴, 3 내지 12원 헤테로사이클릴알킬, C6-C20 아릴 및 5 내지 20원 헤테로아릴로 이루어진 군에서 선택되고,여기서 상기 알킬, 할로알킬, 하이드록시알킬, 알콕시알킬, 아미노알킬, 알켄일, 알킨일, 알콕시, 사이클로알킬, 사이클로알킬알킬, 헤테로사이클릴, 헤테로사이클릴알킬, 아릴 및 헤테로아릴은 각각 수소, 할로겐, 히드록시, 시아노, 니트로, -SRa, -S(=O)Ra, -S(=O)2Ra, -NRbRc, -CO2Rb, -CO-NRbRc, C1-C10 알킬, C1-C4 할로알킬, C1-C4 하이드록시알킬, C1-C4 알콕시알킬, C1-C4 아미노알킬, C2-C10 알켄일, C2-C10 알킨일, C1-C4 알콕시, C3-C10 사이클로알킬, C4-C10 사이클로알킬알킬, 3 내지 10원 헤테로사이클릴, 3 내지 10원 헤테로사이클릴알킬, C6-C12 아릴 및 5 내지 12원 헤테로아릴로 이루어진 군에서 선택된 하나 이상의 치환기로 치환될 수 있다.
- 제1항에 있어서,상기 화학식 1로 표시되는 화합물은 하기 화합물들로 구성된 군에서 선택되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염:1) (S)-6-브로모-2-(2,5-디메틸-1-(4-모르폴리노페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;2) (S)-6-브로모-2-(2,5-디메틸-1-(3-모르폴리노페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;3) (S)-6-브로모-2-(2,5-디메틸-1-(3-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;4) (S)-6-브로모-2-(2,5-디메틸-1-(4-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;5) (S)-(4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(모르폴리노)메탄온;6) (S)-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(모르폴리노)메탄온;7) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)메탄술폰아미드;8) N-(4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)메탄술폰아미드;9) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)메탄술폰아미드;10) (S)-6-브로모-2-(2,5-디메틸-1-(4-(모르폴리노술포닐)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;11) (S)-6-브로모-2-(2,5-디메틸-1-(3-(모르폴리노술포닐)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;12) (S)-N-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)메탄술폰아미드;13) (S)-6-브로모-2-(1-(2,6-디클로로페닐)-2,5-디메틸-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;14) 6-브로모-2-(1-(2,5-디클로로페닐)-2,5-디메틸-1H-피롤-3-일)-N-((S)-1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;15) (S)-6-브로모-2-(1-(3,4-디클로로페닐)-2,5-디메틸-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;16) 6-브로모-2-(1-(2-클로로페닐)-2,5-디메틸-1H-피롤-3-일)-N-((S)-1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;17) 3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-클로로벤젠술폰아미드;18) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-메틸벤젠술폰아미드;19) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-에틸벤젠술폰아미드;20) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤즈아미드;21) (S)-6-브로모-N-(1-(에틸술포닐)피롤리딘-3-일)-2-(1-(3-(2-메톡시에톡시)페닐)-2,5-디메틸-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;22) (S)-6-브로모-N-(1-(에틸술포닐)피롤리딘-3-일)-2-(1-(4-(2-메톡시에톡시)페닐)-2,5-디메틸-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;23) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤젠술폰아미드;24) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤젠술폰아미드;25) (S)-6-브로모-2-(2,5-디메틸-1-페닐-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;26) 3-((6-브로모-2-(1-(2,6-디클로로페닐)-2,5-디메틸-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;27) 3-((6-브로모-2-(2,5-디메틸-1-(4-(모르폴린-4-카르보닐)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;28) 3-((6-브로모-2-(2,5-디메틸-1-(3-(모르폴린-4-카르보닐)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;29) 3-((6-브로모-2-(2,5-디메틸-1-(4-(모르폴리노술포닐)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;30) 3-((6-브로모-2-(2,5-디메틸-1-(3-(모르폴리노술포닐)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;31) 3-((6-브로모-2-(1-(2-클로로페닐)-2,5-디메틸-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;32) 3-((6-브로모-2-(2,5-디메틸-1-(2-메틸-4-(메틸술폰아미도)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;33) 3-((6-브로모-2-(2,5-디메틸-1-(2-메틸-5-(메틸술폰아미도)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;34) 3-((6-브로모-2-(2,5-디메틸-1-(2-메틸-3-(메틸술폰아미도)페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;35) 3-((6-브로모-2-(1-(2,5-디클로로페닐)-2,5-디메틸-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;36) 3-(3-(6-브로모-7-((3-술파모일페닐)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-클로로벤젠술폰아미드;37) 3-((6-브로모-2-(2,5-디메틸-1-(3-모르폴리노페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;38) 3-((6-브로모-2-(2,5-디메틸-1-(3-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;39) 3-((6-브로모-2-(2,5-디메틸-1-(4-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;40) 3-((6-브로모-2-(2,5-디메틸-1-(4-모르폴리노페닐)-1H-피롤-3-일)-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;41) 3-((2-(1-(벤조[d][1,3]디옥솔-5-일)-2,5-디메틸-1H-피롤-3-일)-6-브로모-3H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;42) 3-((6-브로모-2-(1-(3-(2-메톡시에톡시)페닐)-2,5-디메틸-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;43) 3-((6-브로모-2-(2,5-디메틸-1-페닐-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;44) 3-(3-(7-(벤조[d][1,3]디옥솔-5-일-아미노)-6-브로모-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤젠술폰아미드;45) 2-(1-(벤조[d][1,3]디옥솔-5-일)-2,5-디메틸-1H-피롤-3-일)-6-브로모-N-(4-(2-메톡시에톡시)페닐)-3H-이미다조[4,5-b]피리딘-7-아민;46) 3-(3-(6-브로모-7-((4-(2-메톡시에톡시)페닐)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤젠술폰아미드;47) 3-((6-브로모-2-(2,5-디메틸-1-(피리딘-3-일)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;48) 3-((6-브로모-2-(2,5-디메틸-1-(피리딘-4-일메틸)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;49) (S)-2-(1-(벤조[d][1,3]디옥솔-5-일)-2,5-디메틸-1H-피롤-3-일)-6-브로모-N-(1-(에틸술포닐)피롤리딘-3-일)-3H-이미다조[4,5-b]피리딘-7-아민;50) N-(3-(3-(7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)메탄술폰아미드;51) N-(3-(3-(6-클로로-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)메탄술폰아미드;52) (S)-6-클로로-2-(2,5-디메틸-1-(4-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;53) (S)-2-(2,5-디메틸-1-(4-(2-모르폴리노에톡시)페닐)-1H-피롤-3-일)-N-(1-(에틸술포닐)피롤리딘-3-일)-1H-이미다조[4,5-b]피리딘-7-아민;54) (S)-(3-(3-(6-클로로-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(모르폴리노)메탄온;55) (S)-(3-(3-(7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(모르폴리노)메탄온;56) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디에틸아미노)에틸)벤즈아미드;57) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디에틸아미노)에틸)벤즈아미드;58) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤조산;59) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)벤조산;60) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-((디메틸아미노)메틸)벤즈아미드;61) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)-N-메틸벤즈아미드;62) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)벤즈아미드;63) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)-N-메틸벤즈아미드;64) (S)-N-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)-2-(디메틸아미노)아세트아미드;65) (S)-N-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)-2-(4-메틸피페라진-1-일)아세트아미드;66) (S)-N-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)-2-모르폴리노아세트아미드;67) (S)-(4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(4-메틸피페라진-1-일)메탄온;68) (S)-(3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)페닐)(4-메틸피페라진-1-일)메탄온;69) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-모르폴리노에틸)벤즈아미드;70) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-모르폴리노에틸)벤즈아미드;71) (S)-3-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(4-메틸피페라진-1-일)에틸)벤즈아미드;72) (S)-4-(3-(6-브로모-7-((1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(4-메틸피페라진-1-일)에틸)벤즈아미드;73) N-(4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)-2-(디메틸아미노)아세트아미드;74) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-(디메틸아미노)아세트아미드;75) N-(4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)-2-(4-메틸피페라진-1-일)아세트아미드;76) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-(4-메틸피페라진-1-일)아세트아미드;77) N-(4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)-2-모르폴리노아세트아미드;78) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-모르폴리노아세트아미드;79) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)-3-(디메틸아미노)프로판아미드;80) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-3-(디메틸아미노)프로판아미드;81) (3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)(4-메틸피페라진-1-일)메탄온;82) 3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)-2-메틸벤즈아미드;83) (3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)(모르폴리노)메탄온;84) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)-2-(디메틸아미노)아세트아미드;85) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)-2-모르폴리노아세트아미드;86) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)-3-(디메틸아미노)프로판아미드;87) N-(3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-2-메틸페닐)-2-(4-메틸피페라진-1-일)아세트아미드;88) N-(3-(3-(6-브로모-7-((3-술파모일페닐)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-모르폴리노아세트아미드;89) N-(3-(3-(6-브로모-7-((3-술파모일페닐)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-(4-메틸피페라진-1-일)아세트아미드;90) N-(3-(3-(6-브로모-7-((3-술파모일페닐)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)-2-(디메틸아미노)아세트아미드;91) (3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)(모르폴리노)메탄온;92) (3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-4-메틸페닐)(4-메틸피페라진-1-일)메탄온;93) 3-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)-4-메틸벤즈아미드;94) 3-((6-브로모-2-(2,5-디메틸-1-(2-메틸-5-(모르폴린-4-카르보닐)페닐)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;95) 3-((6-브로모-2-(2,5-디메틸-1-(2-메틸-5-(4-메틸피페라진-1-카르보닐)페닐)-1H-피롤-3-일)-1H-이미다조[4,5-b]피리딘-7-일)아미노)벤젠술폰아미드;96) 3-(3-(6-브로모-7-((3-술파모일페닐)아미노)-1H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-N-(2-(디메틸아미노)에틸)-4-메틸벤즈아미드;97) (4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)(4-메틸피페라진-1-일)메탄온;98) (4-(3-(6-브로모-7-(((S)-1-(에틸술포닐)피롤리딘-3-일)아미노)-3H-이미다조[4,5-b]피리딘-2-일)-2,5-디메틸-1H-피롤-1-일)-3-메틸페닐)(모르폴리노)메탄온.
- 제1항의 화학식 1로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염을 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물.
- 제7항에 있어서,상기 화합물은 단백질 키나아제 활성을 억제하는 것을 특징으로 하는 약학적 조성물.
- 제8항에 있어서,상기 단백질 키나아제는 MLK1, MLK2, MLK3, MLK4, DLK, LZK, ZAK 및 LRRK2로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 약학적 조성물.
- 제7항에 있어서,상기 암은 가성점액종, 간내 담도암, 간모세포종, 간암, 갑상선암, 결장암, 고환암, 골수이형성증후군, 교모세포종, 구강암, 구순암, 균상식육종, 급성골수성백혈병, 급성림프구성백혈병, 기저세포암, 난소상피암, 난소생식세포암, 남성유방암, 뇌암, 뇌하수체선종, 다발성골수종, 담낭암, 담도암, 대장암, 만성골수성백혈병, 만성림프구백혈병, 망막모세포종, 맥락막흑색종, 미만성거대B세포림프종, 바터팽대부암, 방광암, 복막암, 부갑상선암, 부신암, 비부비동암, 비소세포폐암, 비호지킨림프종, 설암, 성상세포종, 소세포폐암, 소아뇌암, 소아림프종, 소아백혈병, 소장암, 수막종, 식도암, 신경교종, 신경모세포종, 신우암, 신장암, 심장암, 십이지장암, 악성 연부조직 암, 악성골암, 악성림프종, 악성중피종, 악성흑색종, 안암, 외음부암, 요관암, 요도암, 원발부위불명암, 위림프종, 위암, 위유암종, 위장관간질암, 윌름스암, 유방암, 육종, 음경암, 인두암, 임신융모질환, 자궁경부암, 자궁내막암, 자궁육종, 전립선암, 전이성 골암, 전이성뇌암, 종격동암, 직장암, 직장유암종, 질암, 척수암, 청신경초종, 췌장암, 침샘암, 카포시 육종, 파제트병, 편도암, 편평상피세포암, 폐선암, 폐암, 폐편평상피세포암, 피부암, 항문암, 횡문근육종, 후두암, 흉막암, 및 흉선암으로 이루어진 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 약학적 조성물.
- 제1항의 화학식 1로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염을 유효성분으로 함유하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물.
- 제11항에 있어서,상기 퇴행성 뇌질환은 알츠하이머 질환, 다운 신드롬, 파킨슨 질환, 루게릭병, 치매, 헌팅턴 질환, 다발성 경화증, 근위측성 측삭 경화증, 중풍, 뇌졸중 및 경도 인지장애로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 약학적 조성물.
- 제1항의 화학식 1로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염을 유효성분으로 함유하는 비알코올성 지방간 질환의 예방 또는 치료용 약학적 조성물.
- 제13항에 있어서,상기 비알코올성 지방간 질환은 비알코올성 지방간, 비알코올성 지방간염, 간경변 및 간암으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 약학적 조성물.
- 제1항의 화학식 1로 표시되는 화합물 또는 이의 입체 이성질체, 용매화물, 수화물 또는 약학적으로 허용되는 염을 유효성분으로 함유하는 인플루엔자 질환의 예방 또는 치료용 약학적 조성물.
- 제15항에 있어서,상기 인플루엔자는 A형 인플루엔자 또는 B형 인플루엔자인 것을 특징으로 하는 약학적 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3148490A CA3148490A1 (en) | 2019-08-30 | 2020-08-31 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
EP20857012.7A EP4023647A4 (en) | 2019-08-30 | 2020-08-31 | IMIDAZOPYRIDINL DERIVATIVES AND PHARMACEUTICAL COMPOSITION WITH THEM AS AN ACTIVE SUBSTANCE |
US17/637,000 US20220396575A1 (en) | 2019-08-30 | 2020-08-31 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
CN202080060614.2A CN114555595B (zh) | 2019-08-30 | 2020-08-31 | 咪唑并吡啶衍生物及将其作为有效成分的药学组合物 |
JP2022513547A JP7345220B2 (ja) | 2019-08-30 | 2020-08-31 | イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物 |
AU2020337720A AU2020337720B2 (en) | 2019-08-30 | 2020-08-31 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
ZA2022/01888A ZA202201888B (en) | 2019-08-30 | 2022-02-14 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190107013 | 2019-08-30 | ||
KR10-2019-0107013 | 2019-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021040502A1 true WO2021040502A1 (ko) | 2021-03-04 |
Family
ID=74683886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/011663 WO2021040502A1 (ko) | 2019-08-30 | 2020-08-31 | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220396575A1 (ko) |
EP (1) | EP4023647A4 (ko) |
JP (1) | JP7345220B2 (ko) |
KR (1) | KR102459614B1 (ko) |
CN (1) | CN114555595B (ko) |
AU (1) | AU2020337720B2 (ko) |
CA (1) | CA3148490A1 (ko) |
WO (1) | WO2021040502A1 (ko) |
ZA (1) | ZA202201888B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022182029A1 (ko) * | 2021-02-26 | 2022-09-01 | 주식회사 티에스디라이프사이언스 | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056155A1 (en) * | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
WO2009012283A1 (en) * | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009029609A1 (en) * | 2007-08-27 | 2009-03-05 | Wyeth | Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
KR20110036602A (ko) * | 2008-07-03 | 2011-04-07 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체 |
WO2011038572A1 (en) | 2009-09-29 | 2011-04-07 | Glaxo Group Limited | Novel compounds |
KR20150002639A (ko) * | 2012-03-30 | 2015-01-07 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Mnk1 및 mnk2 조절제로서 바이시클릭 헤테로시클릭 및 이의 용도 |
KR20180021255A (ko) | 2013-12-02 | 2018-02-28 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 표시 장치 및 그 제조방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009324894B2 (en) * | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
RS57869B1 (sr) * | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
AU2012267556B9 (en) * | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
CA2933767C (en) * | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
RU2742122C2 (ru) * | 2014-10-06 | 2021-02-02 | Мерк Патент Гмбх | Соединения гетероарила в качестве ингибиторов ткб и их применение |
MX2017015357A (es) * | 2015-06-29 | 2018-03-16 | Merck Patent Gmbh | Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos. |
MX2018009773A (es) * | 2016-02-23 | 2018-11-29 | Padlock Therapeutics Inc | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). |
KR102548543B1 (ko) * | 2017-01-11 | 2023-06-29 | 아킬리온 에이비 | 야누스 키나아제 억제제로서 신규한 아미노-이미다조피리딘 유도체 및 그의 약제학적 용도 |
-
2020
- 2020-08-31 CA CA3148490A patent/CA3148490A1/en active Granted
- 2020-08-31 KR KR1020200110419A patent/KR102459614B1/ko active IP Right Grant
- 2020-08-31 CN CN202080060614.2A patent/CN114555595B/zh active Active
- 2020-08-31 JP JP2022513547A patent/JP7345220B2/ja active Active
- 2020-08-31 WO PCT/KR2020/011663 patent/WO2021040502A1/ko unknown
- 2020-08-31 US US17/637,000 patent/US20220396575A1/en active Pending
- 2020-08-31 EP EP20857012.7A patent/EP4023647A4/en active Pending
- 2020-08-31 AU AU2020337720A patent/AU2020337720B2/en active Active
-
2022
- 2022-02-14 ZA ZA2022/01888A patent/ZA202201888B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056155A1 (en) * | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
WO2009012283A1 (en) * | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009029609A1 (en) * | 2007-08-27 | 2009-03-05 | Wyeth | Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
KR20110036602A (ko) * | 2008-07-03 | 2011-04-07 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체 |
WO2011038572A1 (en) | 2009-09-29 | 2011-04-07 | Glaxo Group Limited | Novel compounds |
KR20150002639A (ko) * | 2012-03-30 | 2015-01-07 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Mnk1 및 mnk2 조절제로서 바이시클릭 헤테로시클릭 및 이의 용도 |
KR20180021255A (ko) | 2013-12-02 | 2018-02-28 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 표시 장치 및 그 제조방법 |
Non-Patent Citations (5)
Title |
---|
JANG YJ ET AL., ANTIVIRAL RES, vol. 107, 2014, pages 66 - 75 |
MELNIKOVA, I. ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 3, 2004, pages 993 |
MOLECULES, vol. 19, 2014, pages 8189 - 8211 |
See also references of EP4023647A4 |
SHIN JS ET AL.: "Animal Experimentation Committee of the Korea Research Institute of Chemical Technology", J MICROBIOL, vol. 55, 2017, pages 979 - 983 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022182029A1 (ko) * | 2021-02-26 | 2022-09-01 | 주식회사 티에스디라이프사이언스 | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20220396575A1 (en) | 2022-12-15 |
CN114555595A (zh) | 2022-05-27 |
KR102459614B1 (ko) | 2022-10-31 |
KR20210028122A (ko) | 2021-03-11 |
AU2020337720B2 (en) | 2024-02-15 |
JP2022547436A (ja) | 2022-11-14 |
CN114555595B (zh) | 2023-12-26 |
JP7345220B2 (ja) | 2023-09-15 |
CA3148490A1 (en) | 2021-03-04 |
AU2020337720A1 (en) | 2022-03-03 |
EP4023647A1 (en) | 2022-07-06 |
EP4023647A4 (en) | 2023-08-16 |
ZA202201888B (en) | 2023-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017222287A1 (ko) | 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2016200101A2 (ko) | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
WO2010064875A2 (en) | Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient | |
WO2020171499A1 (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
WO2020022600A1 (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
WO2018208132A1 (en) | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | |
WO2018155947A1 (ko) | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 | |
WO2019221566A1 (ko) | 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물 | |
WO2020149715A1 (ko) | 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도 | |
WO2020149723A1 (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020235902A1 (ko) | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 | |
WO2021145520A1 (ko) | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2017176040A1 (ko) | Ras를 분해하는 이종원자고리화합물 및 이의 용도 | |
WO2021040502A1 (ko) | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 | |
WO2021145655A1 (ko) | 신규한 피라졸 유도체 | |
WO2018021826A1 (ko) | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2016006975A2 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
WO2012030170A2 (ko) | 카나비노이드 1 수용체 저해제로 작용하는 신규 화합물 | |
WO2016006974A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2021096112A1 (ko) | 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2022103149A1 (ko) | 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2020013531A1 (ko) | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
WO2022182205A1 (ko) | 신규한 피라졸 유도체 | |
WO2021125800A1 (ko) | 신생혈관형성인자의 억제를 위한 화합물 및 그 용도 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20857012 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3148490 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022513547 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020337720 Country of ref document: AU Date of ref document: 20200831 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020857012 Country of ref document: EP Effective date: 20220330 |